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ABSTRACT 
 
The incidence of ergot toxicity or ergotism has increased in Western Canada in recent 
years and resulted in significant economic losses to the livestock farming industry. 
Chronic ergot toxicity is known to cause severe vasoconstriction through the activation of 
alpha (α)-adrenergic and serotonergic receptors on vascular smooth muscle cells in end 
arterioles. Ergotism may also result in abortion. Despite extensive research in the 
mechanism of ergot toxicity, very little is known about the vascular effects of acute 
exposure to ergot alkaloids or the mechanism of these effects.  Similarly, almost nothing 
is known about the effects of ergot alkaloids on the umbilical vasculature after 45-days of 
exposure to ergot alkaloids. Two studies were performed in sheep to address these two 
important questions in acute and chronic exposure. We hypothesized that acute single-
dose exposure to ergot alkaloids increases the contractile response in the pedal artery 
through the activation of alpha1 (α1)- adrenergic and serotonergic receptors. We also 
hypothesized that terazosin (TE), a selective α1- adrenergic blocker, would abolish the 
effect of ergot exposure. Our last hypothesis was that a 45-day ergot exposure to ergot 
alkaloids increases the phenylephrine (PE) contractile response in the isolated umbilical 
artery and vein as well as the maternal pedal artery.    
 
In the first study, twelve adult sheep were randomly placed into control and exposure 
groups. The exposure group received a single oral dose of ergot alkaloids obtained from 
ground sclerotia (600 µg/kg BW) while the control group received only a water placebo. 
The PE and serotonin contractile responses were assessed in the pedal artery (dorsal 
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metatarsal III artery) dissected six hours after exposure. The effect of an α1-adrenergic 
blocker (TE) was also evaluated. This study demonstrated that acute exposure to ergot 
alkaloids resulted in a significant increase in PE contractile response compared to the 
control group (Ctl EC50 = 1.74 x 10
-6 M; Exp EC50 = 1.079 x 10
-6 M, P = 0.046). 
However, there was no significant difference in serotonergic contractile response (P = 
0.12) between the two groups. TE treatment resulted in a significant dose-dependent 
increase in EC50 in both the exposure and the control group (P < 0.05 for all treatments). 
Surprisingly, the effect of TE was significantly more pronounced in the ergot exposed 
group compared to the control group at two of the three concentrations of TE (TE 30 nM, 
P = 0.36; TE 100 nM, P < 0.001; TE 300 nM, P < 0.001). We concluded that the acute 
effects of ergot exposure are mainly mediated through the activation of α1-adrenergic 
receptors and not serotonergic receptors. TE appears to be more potent in blocking the PE 
contractile response in sheep exposed to ergot compared to the control group. This study 
may indicate that the dry gangrene seen in sheep, and likely other species, is related to the 
activation of α1-adrenergic receptor. This effect may be reversed by using TE especially 
during the early stages of the disease before cell death occurs. This study may also 
indicate that the acute single dose exposure scenario may be useful in the study of the 
vascular effects of ergot alkaloids. 
                                                                                                                                                                                                                                                   
The objectives of the second study were to determine the effects of chronic ergot alkaloid 
exposure on PE contractile response in the umbilical vasculature, as well as the maternal 
pedal artery of pregnant sheep. Twelve adult pregnant sheep were utilized in this study, 
and were randomly placed into groups; six of which received a pelleted diet containing 
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ergot (46 µg/kg BW) while the control group received the uncontaminated pelleted feed. 
This study showed that 45-days of oral exposure to ergot alkaloids resulted in a 
significant increase in PE contractile response in the umbilical artery (Ctl EC50 = 3.962 x 
10-6 M; Exp EC50 = 1.161 x 10
-6 M, P < 0.0001) and the umbilical vein (Ctl EC50 = 7.889 
x 10-6 M; Exp EC50 = 6.801 x 10
-7 M, P < 0.0001), but not in the maternal pedal artery 
(Ctl EC50 = 4.331 x 10
-6 M; Exp EC50 = 4.856 x 10
-6 M, P = 0.3927). A significantly 
lower fetal weight was also found in ergot exposed sheep compared to the control group 
(control, 3.3 ± 0.17 kg; exposure 2.07 ± 0.13 kg, P = 0.0002), (T-test, GraphPad Prism). 
This is the first study to report increased contractility in the umbilical vasculature after 
45-days of oral ergot exposure. The mechanism of which is, at least in part, related to the 
activation of α1-adrenergic receptors. The concentration selected in this study is below 
the allowed limits set by the Canadian Food Inspection Agency in sheep which 
recommends that ergot levels in feed be less than 600 ppb. This study indicates that there 
is an urgent need to revisit these standards as negative effects can occur at lower 
concentrations.   
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CHAPTER 1: Introduction and Literature Review 
 
1.1 General Introduction 
 
In recent years, there has been an increasing interest in the toxicity related to the 
consumption of ergot by livestock due to increased incidence and significant economic 
impact on the farming industry in the US and Western Canada 41, 44. Ergot toxicity is 
caused by the chronic ingestion of ergot alkaloids produced by fungal organisms in the 
family Clavicipitaceae. Livestock is exposed to ergot alkaloids through the consumption 
of grains and grasses infected with Claviceps spp or tall fescue infected with 
Neotyphodium spp 6, 37. 
 
The mechanism of ergot toxicity in livestock is thought to be related to the similarity of 
the structure of ergot alkaloids acting as agonists or partial agonists and sometimes as an 
antagonist to physiologic monoamine neurotransmitters: epinephrine, serotonin, and 
dopamine, causing vasoconstriction and inhibition of prolactin secretion 27. The effects of 
ergot toxicity can range from subclinical signs such as weight loss and decreased milk 
production to more severe signs such as necrosis of the tail and loss of the extremities due 
to dry gangrene 14, 101, 105.  
 
The gangrenous form is the most common clinical manifestation of this disease in 
livestock and is caused by perturbation of vascular function occurring after chronic 
exposure. Very little is known about the vascular effects of acute ergot alkaloid exposure 
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in livestock or their mechanisms. The effects of ergot alkaloids on the umbilical 
vasculature and the mechanism of these effects are also unknown. This thesis aims to 
address these two important questions.    
 
1.2 Historical Review of Ergot and Ergotism 
 
The first mention of ergot in history was around 600 BC where it was referred to as “a 
noxious pustule in the ear of grain” on an Assyrian cuneiform tablet 112. Another 
description of ergot appeared in the sacred books of the Parsees around 350 BC where it 
was described as “a noxious grass that causes pregnant women to drop the womb and die 
in childbed” 16. The term ‘ergot’ itself comes from Old French, which means the cock’s 
spur. This term has been used to describe the appearance of the “sclerotium,” the ergot-
containing fungal body that is black and spur-like in shape 37. 
 
Devastating epidemics of ergotism, also known as St. Anthony’s Fire disease, can be 
traced back to the middle age7, 105. During that time, the disease became widespread in 
many parts of Western Europe and was caused by the consumption of rye bread 
contaminated with ergot produced by Claviceps purpurea.  Rye bread, being very cheap, 
was fed only to the poor during times of famine. To increase the amount of bread 
produced, and to fulfill the need during the shortage, large amounts of ergot-
contaminated grain was used, which greatly exacerbated the epidemic 58, 112.  
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The consumption of ergot-contaminated feed produces two syndromes: a convulsive and 
a gangrenous syndrome. The convulsive syndrome was first described in Paris, France, 
and was associated with the disturbances of the central nervous system causing 
hallucinations, twitches, and muscle spasms. The gangrenous syndrome was 
characterized by dry gangrene, necrosis and eventually spontaneous auto-amputation of 
the appendages. It was first described in Germany 5, 37, 59, 112. During the epidemics, many 
died from ergotism, however, some survived. Many of those who survived received 
treatment at the hospitals of the Anthonines where the malady was believed to be cured 
by holy water or wine sprinkled with the bone of the Egyptian hermit, St. Anthony (251-
356 AD)! It is, however, thought that patients were actually cured because they only ate 
non-contaminated bread during hospitalization. The gangrenous syndrome was often 
associated with a burning sensation of the affected appendage and was later called ‘Holy 
Fire,’ ‘ignis saucer’ or St. Anthony’s Fire 5, 16, 58. 
 
Ergot also played an important role in human medicine. It was often used by midwives in 
Europe as a substance to induce parturition, initiate abortion and control postpartum 
bleeding 16, 37. This was due to its powerful effect on the uterus producing uterine 
contraction. However, the use of ergot was discontinued at the end of the 19th century as 
the complications associated with its use raised many concerns among physicians. Due to 
the large variation of active ingredients within sclerotia, quite often the accuracy of 
dosage of the treatment could not be controlled. David Hosack, a physician from New 
York, described it as ‘the pulvis ad mortem’, i.e., death powder, as he noticed many 
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stillbirths associated with its use were related to prolonged uterine contractions during 
delivery 59. 
 
Since ergot sclerotia had a long history of medical benefits, several attempts were made 
to reveal the hidden active chemical components. The German pharmacist Heinrich 
Wiggers was the first to attempt to isolate the active constituents within ergot sclerotia. 
However, his attempt in 1835, was not successful 4. Later in 1864, Wenzell described two 
peculiar alkaloids in rye which he called “Ecboline and Ergotine” and claimed them to be 
the active ingredients within the ergot sclerotia 4, 58, 59. In 1875, the first ergot alkaloid 
was isolated by Tanret ,in Paris, who was able to extract the alkaloid in a crystallized 
form and named it ‘ergotinine’ 4. 
 
The discovery of this active ingredient of ergot opened the door for isolating many new 
active alkaloids. For example, ergotoxine was discovered by Dale and Barger in London 
in 1906 59. However, in 1943, Arthur Stoll and Albert Hofmann demonstrated that 
ergotoxine was, in fact, a mixture of three alkaloids closely related in chemical structure; 
ergocornine, ergocristine, and ergocryptine. The same group was later able to isolate 
ergotamine, which was shown to be a vasoactive 4, 59, 60, 82. As a medicinal drug, 
ergotamine was first introduced to human medicine by the work of John Grahm and 
Harold Wolff who showed that it could be used in patients suffering from migraine 
headaches in 1938 5, 59.  
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Nowadays, the use of ergotamine to treat a migraine has decreased in popularity due to its 
side effects and the development of more effective and safer drugs. LSD is another ergot 
alkaloid derivative used in humans after its discovery by Albert Hoffmann in 1983. As a 
potent hallucinogen, its use was common by secret services who would administer it to 
people during interrogation 37. In human medicine, LSD has also been used in the 
treatment of many neurologic and endocrine disorders because of its action on 
dopaminergic receptors 34, 60.  
 
Currently, ergotism is rare in human medicine due to the advancement in the cleaning 
and milling processes, as well as the establishment of regulatory limits for ergot alkaloids 
in grains. Periodically, patients still suffer from ergot related complications due to the 
long-term and excessive use of ergotamine for migraine headache treatment and the use 
of ergot alkaloids in patients with underlying debilitating conditions such as acquired 
immunodeficiency syndrome (AIDS) or cardiovascular diseases 33. Nevertheless, 
ergotism is still seen in veterinary medicine. This devastating disease primarily affects 
forage grazing animals such as sheep, cattle, and horses 15.  
 
1.3 Ergot Alkaloids: Sources, Lifecycle, Incidence and Allowable limit 
 
1.3.1 Sources of Ergot Alkaloids 
 
Ergot alkaloids are naturally occurring mycotoxins of clinical importance in human and 
veterinary medicine which are produced by two different genera of fungi in the family of 
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Clavicipitaceae. This fungal family includes the external spore-producing fungi 
(Claviceps spp.) and endophytic fungi (Neotyphodium spp.)29, 30, 105.  
 
Fungi in the Claviceps genus are the main source of ergot alkaloid producing organisms 
in Western Canada and Europe and will be the focus of our study. The predominant and 
most prevalent species responsible for economic losses to livestock is Claviceps 
purpurea 11, 64, 68. This species produces dark, hard, resting, yet infective fungal bodies 
known as ‘sclerotia’ which are visible to the naked eye. These fungal bodies contain the 
pharmacologically active mixture of ergot alkaloids and serve as asexual spores. The 
most susceptible host plants include barley, wheat, rye and durum, which are commonly 
grown in Saskatchewan 64. The clinical syndromes associated with the ingestion of plants 
infected by Claviceps is known as ergotism.  In contrast to Claviceps spp., the infective 
stage of Neotyphodium spp. are invisible to the naked eye as it develops inside the 
embryo of the infected seed and remains alive during the lifecycle of the plant. Therefore, 
microscopic evaluation of suspected plants is required to confirm fungal infection 37.  
 
Claviceps purpurea produces no known benefits to infected plants and is, therefore, 
considered parasitic in nature. It is thought that the ergot sclerotia may result in the 
replacement of the seeds causing a significant drop in yield. On the contrary, 
Neotyphodium infection of plants is known to be symbiotic as the infection allows the 
plant to become more drought, stress, and disease resistant. This infection is most 
common in the US and is of great economic importance 41, 92. The clinical syndromes 
associated with the ingestion of Neotyphodium spp. are known as fescue toxicosis. It is 
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estimated to cost US ranchers more than $860 million annually 41. Since it is a costly 
disease to livestock, this syndrome has received great attention in the past 50 years in the 
US. Although ergotism and fescue toxicosis are clinically similar, the endophyte-infected 
(Neotyphodium coenophialum) tall fescue contains not only a lower alkaloid content, but 
also a different mixture of alkaloids when compared to the sclerotia of Claviceps 
purpurea 27, 79. The main ergopeptine alkaloid associated with fescue toxicosis is 
ergovaline, while the most commonly incriminated alkaloid associated with ergotism is 
ergotamine 28. The ergot alkaloid content in samples from rye and wheat flour have 
shown that the six alkaloids that are abundant in these crops are ergometrine, ergosine, 
ergotamine, ergocornine, ergocryptine, and ergocristine. Nonetheless, studies conducted 
to examine the ergot alkaloid content in Canadian rye, wheat, triticale, and barley found 
that the alkaloid content was different in sclerotia from the same head, field, and region! 
Ergocristine was the most abundant alkaloid in wheat, barley, and rye from Western 
Canada while ergotamine was the predominant alkaloid in Eastern Canada 27, 28, 64. 
 
1.3.2 The Lifecycle of Ergot (Claviceps purpurea) 
 
The sclerotia are also known as the overwintering external bodies and appear as black 
cockspur-like seeds of variable sizes which protrude from the plants’ florets 30. Once 
mature, they become dormant and resistant to harsh environmental conditions allowing 
them to survive during winter and post-harvest. The size of sclerotia, as well as their 
alkaloid content, varies significantly depending on the host plants and environmental 
conditions 56. The sclerotia fall off to the ground during harvest and can germinate only if 
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its dormancy is interrupted by several weeks of cold temperature. The preferred 
environmental temperature for its germination is around 0 °C which should be 
maintained for at least four to eight weeks, and is ideally followed by a temperature close 
to 18 °C for several weeks 66. The germination process can also be interrupted if the soil 
is too dry, but will proceed as soon as the moist conditions are restored. Germination 
typically starts in the early spring when the soil is still moist and results in the production 
of numerous slender bodies known as asci (singular, ascus). Each ascus contains eight 
ascospores which are typically produced when grasses are flowering 91. With the help of 
a wind current, windborne insects and birds, these ascospores reach the stigma of the 
flowering plant, attach and invade the ovary, and establish a primary infection. In 
general, plants with a longer duration of flowering are more susceptible to infection. Rye, 
in particular, is considered very susceptible to infection having not only a long flowering 
season, but also an open floret structure 64.  
 
Once in the ovary, the ascospores develop into conidia which mix with plant sap arising 
from the site of infection to form the “honeydew”. This sticky syrup attracts flying 
insects which help spread the infection to other plants. The honeydew containing conidia 
may also be carried by heavy rain and wind expanding the infected area 37, 64, 66. The 
infection established by the honeydew containing conidia is known as the secondary 
infection. Approximately ten days post-infection, conidia begin to mature and form the 
rind of sclerotium, which harden and change their shape as time passes becoming the 
mature sclerotia 37, 66, 91. See Figure 1.3-1. 
 
9 
 
 
Figure 1.3-1 The lifecycle of ergot (Clavicep purpurea) infesting cereals or other 
grasses. Modified and re-drawn from Menzies et al. (2015) 
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1.3.3 The incidence of Ergot in Western Canadian Grains 
 
During the 1980s and 1990s, ergotism was not reported as a significant clinical problem 
for livestock on the Canadian prairies. This was likely due to the absence of sensitive 
laboratory techniques to detect low concentrations of ergot alkaloid in feed 64. Therefore, 
the extent of the problem remains unknown. Canada is known to be the largest exporter 
of Canadian western amber durum and Canadian western red spring wheat in the world. 
Crops are grown on over five million acres in Western Canada through Manitoba, 
Saskatchewan and Alberta 108.  
 
In 1999, the Canadian Grain Research Laboratory (Winnipeg, MB) conducted a survey 
examining the prevalence of sclerotia in Western Canadian crops 64, 108. The survey 
reported that 4% of CWAD and 12% of the CWRS were contaminated by ergot. In 
Saskatchewan, ergot infection of CWRS was estimated to be 17% with sclerotia 
representing 0.02% (by weight) of the tested sample. In 2005, a large infestation was 
reported in Manitoba, where approximately 10% of the CWRS contained ergot sclerotia. 
Three years later, the ergot infection in the same crop was reported to be significantly 
higher in Manitoba, Saskatchewan, and Alberta reaching 13%, 15%, and 12%, 
respectively 64, 108. The infection rose again in the three provinces in 2011. This time 
reaching alarming concentrations with 15%, 19% and 29% of the tested samples from 
these provinces having high amounts of sclerotia. During the same period, ergot 
contamination of CWAD also rose significantly. In Alberta, the contamination steadily 
increased from 5% in 2008 reaching 10% in 2012. Ergot infection in Saskatchewan crops 
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was not steady, but samples taken in 2008 and 2011 yielded 15% and 14% infection, 
respectively. Data from Manitoba were not sufficient to produce a meaningful pattern of 
infection due to the small sample size. Overall, the data showed that the incidence and 
severity of ergot infection increased significantly in both CWAD and CWRS crops 
during the examination period 64, 108. A high degree of ergot contamination in crops often 
results in severe downgrading penalties or even complete rejection of the infected grain, 
which can be devastating for the industry. Due to the prolonged wet and cold conditions 
in Western Canada, the number of downgraded samples from crops have increased 
significantly in recent years 64, 68, 108.  
 
1.3.4 Allowable Ergot Limits in Livestock Feed 
 
There are varied allowable limits of ergot alkaloid content within livestock feed in the 
literature. The toxicity of ergot alkaloids depends not only on the concentration of 
alkaloids within the contaminated feed, but also on the specific mixture of alkaloids 
present as different alkaloids have variable potencies 15, 27, 56. In cereal grains destined for 
human consumption, acceptable concentrations of total ergot contamination in the US, 
Canada, EU and Australia are less than 0.05% by weight 28.  
 
The legislation is in place in Canada which sets the maximum allowable concentrations 
of ergot alkaloids within cattle and swine feed at 2 to 3 and 4 to 6 ppm, respectively 14. It 
is also recommended that pregnant and lactating animals receive a diet with levels less 
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than 250 ppb to avoid abortion and agalactia. In the US and EU, concentrations that are 
less than 0.1 and 0.3 ppm total ergot are acceptable 14, 27, 28.   
 
It is worth mentioning that these legislated allowable limits were not established through 
comprehensive toxicological studies in livestock in most cases. In fact, adverse effects 
have been reported at levels as low as 100 ppb in livestock depending on overall health 
status, alkaloid mixture and environmental conditions 27, 28. The variation in reported 
adverse effects on livestock health resulted in inconsistent recommendations of tolerable 
limits. Calves and horses are known to be very susceptible to ergotism whereas poultry 
have the greatest tolerance27, 28. Furthermore, it is important to note that cold weather 
conditions exacerbate the clinical signs of ergot toxicity 35.  It is, therefore, important to 
create allowable limits which address the difference in species susceptibility and also take 
into account climate differences in each region. 
 
1.4 Mechanisms of Action of Ergot Alkaloids 
 
Understanding ergot alkaloids and mechanisms related to their toxicity are challenging 
considering the variety of factors affecting their biological activity such as the alkaloid 
concentration and content, types of alkaloid producing plants and the host species. 
Nonetheless, all ergot alkaloids share a common chemical structure, i.e., the ergoline ring 
(D-lysergic acid ring structure) which makes their biological activity more predictable 37.  
The ergoline ring (Figure 1.4-1a) is the key structure thought to be responsible for 
toxicity in domestic animals.  This is related to the similarity of this ring to active 
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biological amines in susceptible species including serotonin, epinephrine, and dopamine 
(Figure 1.4-2).   
 
The mechanism of toxicity and its variability of effects is related to the broad specificity 
of the interactions between the ergoline ring and the receptors for these active biological 
amines. These receptors are heterogeneous in nature with at least fourteen subtypes of 5-
HT receptors, ten subtypes of adrenergic receptors and five subtypes of dopamine 
receptors 76. Thus, ergot alkaloids can act as either agonist, partial agonist or antagonist 
depending on the types of ergot alkaloids, the location of the receptors in tissue, and the 
host species.  
 
The ergoline ring is methylated at N-6 and has a functional group on C-8. The 
substitution of this functional group plays a role in determining the activity of each 
compound and, likewise, is used to classify ergot alkaloids into three groups: clavines, 
lysergic acid derivatives, and ergopeptines (Figure 1.4-1b to Figure 1.4-1d). Alkaloids in 
the group of ergopeptines such as ergotamine and its derivatives are responsible for ergot 
poisoning and fescue toxicosis in veterinary medicine. The physiological effects seen in 
animals range from subclinical effects such as decreased weight gain, loss of appetite, 
changes in thermoregulation and reduced fertility; to pronounced clinical effects such as 
loss of extremities and abortion 80, 101, 102, 107. 
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Figure 1.4-1 Chemical structure of ergoline rings as well as three different classes of 
ergot alkaloids determined by the nature of the functional group at C-8 : (a) Ergoline ring 
system in ergot alkaloids; (b) represent structure of clavine alkaloids; (c) represent 
structure of lysergic acid derivertives; (d) represent structure of ergopeptine alkaloids. 
Modified from Flieger et al. (1997) and Haarmann et al. (2009)  
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Figure 1.4-2 Comparison of the chemical structures of the ergoline ring system with 
neurotransmitters : (a) Ergoline ring system in ergot alkaloids (b) chemical structure of 
noradrenalin (c) chemical structure of dopamine (d) chemical structure of serotonin. 
Modified from Flieger et al. (1997) and Haarmann et al. (2009) 
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1.4.1 Effects of Ergot Alkaloids on Serotonergic Receptors 
 
It is known that serotonin, also known as 5-hydroxytryptamine (5-HT), receptors are 
divided into four main classes: 5-HT1, 5-HT2, 5-HT3 and 5-HT4. All classes of receptors, 
except for 5-HT3, are members of the G-protein-coupled receptors. The 5-HT3 class 
belongs to the family of ligand-gated ion channels. These classes of receptors are further 
divided into different subtypes and, to date, there are fourteen different types of 
serotonergic receptors each denoted with a letter from A to F after the number 76, 111.   
 
The ergoline ring common to naturally occurring ergot alkaloids allows these alkaloids to 
bind to the different serotonergic receptors on the vasculature with high affinity, but low 
specificity, resulting in variable responses at different receptors 76, 111. Few studies have 
examined the activation of serotonergic receptors by ergot alkaloids in veterinary 
medicine.  Dyer 21 examined the role of adrenergic and serotonergic receptors in 
mediating the effects of ergot alkaloids in the umbilical vasculature. Using sheep as a 
model, he showed that umbilical blood vessels contracted when exposed to serotonin, 
angiotensin, ergot alkaloids, acetylcholine, epinephrine and norepinephrine and 
concluded that both receptor types (adrenergic and serotonergic) are present within the 
umbilical vasculature. Similar to his finding in the umbilical vasculature, he also reported 
that LSD caused a contraction in the isolated ovine uterine artery at late pregnancy, a 
response which was abolished by ketanserin, a 5-HT2 serotonergic receptor antagonist 
113. 
Using ergovaline, Dyer later showed that 5-HT2 receptors and not adrenergic receptors 
produced vascular contraction in isolated bovine uterine and umbilical arteries 22. 
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In the peripheral vasculature, Oliver et al. 1993 demonstrated that serotonin causes the 
bovine lateral saphenous vein and the dorsal metatarsal artery to strongly contract 72. 
Interestingly, when these isolated arteries were pre-incubated with lysergamide and later 
exposed to serotonin or adrenergic agonists, the contraction was significantly weakened 
indicating that lysergamide may act as a partial antagonist at these two locations 72. 
Another in vitro study also showed that thiabendazole, an approved anthelmintic drug in 
livestock with antagonistic activity to serotonergic receptors, was able to partially 
antagonize vasoconstriction induced by serotonin in the bovine pedal vein 73. Klotz et al. 
(2012, 2013 and 2016) demonstrated that chronic exposure to endophyte-infected tall 
fescue caused a significant increase in vascular contractility in the bovine lateral 
saphenous vein in response to serotonin agonists, a response that was reversible 3 months 
after the infected diet was withdrawn. He concluded that the main receptor involved in 
mediating this effect was 5HT-2A 
47, 49, 50. In horses, a single study compared the vascular 
contractile response of alkaloids within Acremonium coenphialum to those of PE and 
serotonin in the dorsal metatarsal artery and lateral saphenous vein. The study found that 
the contraction caused by ergot alkaloids was less than that produced by PE and serotonin 
45. 
 
In humans, acute migraine attacks are often treated with drugs targeting 5-HT1D 
76. These 
attacks commonly cause dilatation of extracerebral intracranial arteries resulting in 
increased vascular pulsation and the stimulation of perivascular branches of the fifth 
cranial nerve. When 5-HT1D receptors are activated by certain medications, these 
pathologically dilated arteries contract resulting in symptomatic relief of a migraine 
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attacks 76. The use of these drugs is also often associated with increased incidence of 
myocardial infarction due to their vasoconstrictive effects on coronary arteries 76, 92. 
 
1.4.2 Effects of Ergot Alkaloids on Alpha (α)-adrenergic receptors 
 
The α-adrenergic receptors are a group of G-protein-coupled receptors which are 
activated by the binding of epinephrine and norepinephrine neurotransmitters. There are 
two main subtypes of α receptors namely α1 and α2. α1- receptors are further subdivided 
into α1A, α1B, and α1D. There is no α1C receptor. Similarly, α2-receptors are divided into 
four subtypes; α2A, α2B, α2C and α2D 76.  
 
Within the vasculature, the distribution of each subtype is variable. However, in general, 
α1-adrenergic receptors are localized postsynaptically within vascular smooth muscle 
cells and cause vasoconstriction in response to sympathetic stimulation. In contrast, α2-
adrenergic receptors are thought to be located in non-innervated effector cells such as 
endothelial cells and platelets 85.  
 
Several studies revealed that ergot alkaloids can act on adrenergic receptors. In 1906, 
Henry Hallett Dale was the first to report that an ergot preparation could cause blood 
pressure to rise in cats, which is similar to the effect of epinephrine 93. To his surprise, 
when these cats were pretreated with ergot and later received epinephrine, blood pressure 
only fell, which showed that the ergot preparation interacted with epinephrine receptors 
19 
 
and may, in fact, act as blockers! This reversal of epinephrine action by ergot is now 
known as Dale’s vasomotor reversal 59, 85, 93.  
 
Most studies examining the effects of ergot alkaloids on adrenergic receptors focused on 
α2-adrenergic receptors. Oliver et al.1998 characterized the adrenergic response to α1 and 
α2 adrenergic agonist drugs in cattle grazing endophyte-infected tall fescue compared to 
control animals. They concluded that only the α2-adrenergic receptor is important to 
mediate the vasoconstrictive effects 74. Similarly, Roquebert et al. 1986 showed that the 
vasoconstriction associated with the administration of dihydroergocryptine is mediated 
by α2-adrenergic receptors 87. Others, however, reported that α1- adrenergic receptor may 
also play a role to mediate the vasoconstriction. For example, Kalkman et al. 1982 43 
reported that both α1 and α2-adrenergic receptors, rather than serotonergic receptors, play 
a role to mediate vasoconstriction after ergometrine injection in rats. Similarly, Larson et 
al. 1996 57 demonstrated that prazosin, which is α1-adrenergic antagonist, can alleviate 
syndromes caused by fescue toxicosis in rats. 
 
1.4.3 Effects of Ergot Alkaloids on Dopaminergic Receptors 
 
Ergot alkaloids also act on dopaminergic receptors. Dopaminergic receptors are involved 
in motor function in the brain and regulate the release of prolactin from the anterior 
pituitary gland. The repeated activation of D2 or D4 dopaminergic receptors within the 
anterior pituitary gland by ergot alkaloids inhibits prolactin secretion resulting in 
decreased milk production, delayed or prolonged parturition as well as other disturbances 
20 
 
in the female reproductive system 11, 76. Luteinizing hormone and prolactin have a 
synergistic effect in promoting progesterone secretion from the corpus luteum 38. The 
disturbance of prolactin secretion could also decrease the progesterone concentration and 
consequently cause a failure to maintain pregnancy. The depression of serum prolactin 
can also be used as a bioindicator of ergot alkaloid exposure 81. In human medicine, 
ergoline derivatives are also used in endocrine disorders such as hyperprolactinemia 
secondary to the excessive secretion of prolactin from pituitary prolactinoma 60.   
 
1.5 Clinical Forms of Ergotism in Livestock 
 
Since there is strict regulation of allowable limits of ergot alkaloids in grains used for 
human food and the advent of improved milling technology, nowadays ergotism is rarely 
seen in human medicine. Nonetheless, it is still a problem in veterinary medicine, 
particularly in susceptible species such as beef cattle and small ruminants 27. It has been 
reported that the annual economic losses related to this disease in the beef industry in the 
US were approaching $2 billion in 1993 41. A 2013 study found that ergotism in the US 
beef cattle industry resulted in decreased calf weaning weight by approximately 22.3 kg 
resulting in losses approaching $500 million every year 44. In general, ergotism in 
livestock can be seen in three different forms: gangrenous, convulsive and an “other” 
form with the later inducing nonspecific clinical signs related to gastrointestinal 
abnormalities, endocrine dysfunction, poor reproductive performance and abnormal body 
temperature regulation 6, 11, 14. 
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1.5.1 Gangrenous Form 
 
Frequently, ergotism in veterinary medicine is seen in the gangrenous form, and this form 
is frequently observed when ergot concentration exceeds 10 g/kg feed 27. Early in the 
course of the disease, animals often show signs of lameness. As the disease progresses in 
severity, prolonged vasoconstriction leads to dry gangrene resulting in loss of peripheral 
tissues such as the tail tip, tongue, ear tips and hoof 11, 14. The speculated pathogenesis of 
this form of ergotism is caused by the very potent vasoconstrictive properties of the ergot 
alkaloids such as ergotoxine, which consequently causes vascular injury and circulatory 
disturbance. One study reported histological lesions in blood vessels after chronic 
exposure to ergovaline where moderate thickening of the tunica media of tail, skin and lip 
arterioles was found 71. It is important to mention that cold weather conditions often 
result in an exacerbation of the toxic effects with one study reporting dry gangrene after 
ergot exposure in pregnant sheep kept outdoors in the cold, but not in animals housed 
indoors 27.  
 
1.5.2 Convulsive Form 
 
The convulsive form of ergotism is mostly caused by the toxins produced by C. 
purpurea, C. paspali and the endophyte fungus Neotyphodium lolii 14, 110. This form is 
often under-diagnosed by veterinarians as animals suffering from this form manifest 
nonspecific clinical signs such as muscle tremors, incoordination, and paralysis which 
often mimic other diseases affecting the nervous system 63. The convulsive form is also 
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known as ‘ryegrass staggers’ as the disease is associated with the ingestion of endophyte-
infected perennial ryegrass 11. This form is sporadic in Western Canada and EU, but more 
frequently reported in South Africa and US.  
 
The neurological signs are related to the indole-diterpenoid tremogens, paspalitrem A, B 
and C, which are commonly produced by C. paspali and N. lolii. These tremogens can 
occasionally be detected in the sclerotia of C. purpurea, but only in small amounts 110. 
Very little is known about the mechanism of action of these tremogens. However, it has 
been postulated that these toxins inhibit the function of GABA receptors 28.  
 
1.5.3 Other Form 
 
The “other” form of ergotism affects thermoregulation, endocrine function and 
reproductive performance 6, 11, 14. During warm weather conditions, blood flow to 
peripheral organs increases to allow for the dissipation of heat from the body core to the 
body surface, or skin, through sweating. Chronic exposure to ergot alkaloids often results 
in widespread peripheral vasoconstriction, thus, limiting the dissipation of heat through 
the skin resulting in hyperthermia. The animal often responds by hyperventilating, which 
is clinically seen as rapid and labored breathing, and also by increasing saliva production 
to dissipate heat 101, 105. The consequences of prolonged hyperthermia include decreased 
feed intake, weight loss, reduced fertility, and poor reproductive performance.  
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The effects of ergot alkaloids on endocrine dysfunction is related to the activation of 
dopaminergic receptors in the pituitary gland which leads to the inhibition of prolactin 
secretion76, 105. In fact, a persistent decrease in serum prolactin is often used as a 
biomarker for ergot alkaloid exposure in livestock in general, and mares in particular 81. 
The low prolactin concentrations often result in decreased milk production which can be 
devastating to dairy farmers 11, 76, 105. 
 
1.6 Effects of Ergot Alkaloids on Different Vascular Beds: What We Know from 
In Vivo and In Vitro Studies 
 
1.6.1 Peripheral and Visceral Blood Vessels 
 
The most common form of ergot poisoning in livestock is the gangrenous form, which 
often occurs during the winter and often affects the tail tip and distal extremities 6, 14, 15, 33, 
40. Consequently, peripheral vasculature such as the dorsal metatarsal, lateral saphenous 
and caudal arteries or veins have been the subject of many classical studies of ergot 
alkaloid toxicity both in vivo and in vitro. Other studies focused on visceral arterial 
vascular beds particularly those related to gastrointestinal absorption.  
 
In vitro studies examining the effects of ergot alkaloids on peripheral vasculature using 
arterial tissue bath include Klotz et al., Oliver et al. and Abney et al. 45, 47, 49-54, 72, 74, 77. All 
of which were discussed previously. Studies examining the clinical effects of ergot 
exposure on the vasculature include Rhodes et al., 1991 and Aiken et al. (2007 and 2014). 
 
24 
 
Rhodes et al. 1991 examined blood flow in different tissues using radiolabeled 
microspheres in sheep and cattle. They showed that castrated sheep receiving a high 
endophyte diet (0.52 ppm ergovaline) had reduced blood flow to the adrenal gland and 
the skin covering the inner hindlimb compared to animals receiving low endophyte diet 
(less than 0.01 ppm ergovaline). In steers, blood flow to the colon, duodenum, cerebellum 
and the skin covering the ribs was similarly reduced after exposure to a high endophyte 
diet. Interestingly, steers that previously received a high endophyte diet, but later 
consumed an endophyte-free diet for 8 days, displayed increased blood flow to the 
coronary bands of the hoof compared to those consuming a normal diet after a low 
endophyte diet 84. 
 
Aiken et al. 2009 examined changes in blood flow on cross-sectional areas of caudal 
artery in heifers after exposure to endophyte-infected tall fescue using Doppler 
ultrasonography. Compared to baseline, i.e., before exposure, they showed that 
endophyte-infected tall fescue exposure resulted in decreased caudal artery total cross-
sectioned area and blood flow within four hours of exposure. Later, they conducted a 
study examining the effects of a similar exposure scenario in goats on carotid and 
auricular arteries. Aiken et al. 2014 again reported decreased cross-sectional area or 
vasoconstriction at both locations in goats 1, 2.   
 
Reduced blood flow after ergot alkaloid exposure has also been reported in arteries 
supplying the uterus, ovary and corpus luteum using ultrasound 13, 36. Other changes in 
visceral vascular beds, in response to ergot exposure, include the studies from Foote et 
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al., 2012 and Egert et al., 2014. Using an arterial tissue bath, Foote et al. showed that 
isolated bovine ruminal artery and vein display vasoconstriction after incubation with 
ergot alkaloids 32. In contrast, Egert et al. reported that mesenteric arteries and veins from 
steers fed endophyte-infected tall fescue for 21-days showed diminished contractility 
after exposure to some ergot alkaloids, suggesting that the exposure to these alkaloids 
may alter nutrient absorption 23. 
 
It is interesting to note that the effects of ergot alkaloids on the vasculature are not limited 
to their role as vasoconstrictors.  For example, Strickland et al. 1996 examined the 
growth promoting effects of ergot alkaloids on VSMC using cell culture. They showed 
that ergonovine and ergocryptine stimulated VSMC growth while ergovaline inhibited 
growth 103. In support, Oliver et al. 2000 showed that chronic exposure to ergot alkaloids 
resulted in moderate thickening of the tunica media of the arterioles of the tail, skin, and 
lips histologically 71. Additionally, Shappell et al. 2003 reported that ergovaline is 
cytotoxic to Caco-2 cells which mimic gastrointestinal epithelium 96. Mulac et al. 2011 
showed that several ergot alkaloids caused apoptosis when incubated with cultured 
human kidney cells with ergocristine being the most potent 70.   
 
1.6.2 Umbilical Blood Vessels 
 
 
Umbilical blood vessels are composed of two umbilical arteries and one umbilical vein. 
The umbilical vein supplies oxygenated blood and nutrients to the fetal side of the 
placenta, while umbilical arteries carry out unwanted waste materials and carbon dioxide 
26 
 
from the fetal circulation. It is now well established, from a variety of studies, that 
umbilical blood vessels lack sympathetic innervation 25, 26, 90. Therefore, the regulation of 
vascular tone in the umbilical vasculature is dependent on locally produced and 
circulating vasoactive catecholamines making them more susceptible to exogenous 
vasoactive compounds 9.  
 
Quite often, when fetal stress occurs, the level of vasoactive compounds within the 
umbilical vasculature changes and results in altered flow, which has implications for fetal 
health 42, 95.  Baker et al. 1992 found that intranasal PE, an inhalant α-adrenergic agonist 
used in human medicine for respiratory congestion, caused decreased umbilical artery 
flow velocity. He suggested that this drug should be prohibited in high-risk pregnancies 3.  
 
The effect of ergot alkaloids on the umbilical vasculature has been examined in three 
studies. In the first study, Dyer demonstrated that serotonergic as well as adrenergic 
receptors are present in isolated ovine umbilical blood vessels 21. Later, he showed that 
ergovaline caused vasoconstriction of ovine umbilical arteries and likely occurs through 
the activation of 5-HT2 receptors 
22. A recent abstract by Klotz et al. 2017also showed 
that ovine umbilical arteries from pregnant sheep fed endophyte-infected tall fescue were 
very responsive to serotonin but not norepinephrine 55. 
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CHAPTER 2: Rationale and Hypotheses 
 
2.1 Rationale 
 
Ergot alkaloids are known to cause severe vasoconstriction and dry gangrene of 
extremities after chronic exposure in livestock. Previous research has indicated that the 
vasoconstriction is related to the activation of adrenergic and serotonergic receptors by 
the ergoline ring of ergot alkaloids. Very few studies have examined these vascular 
effects of chronic exposure in live animals since such long experiments are costly and 
time-consuming. Very little is known about the acute effects of ergot exposure and 
whether these effects mimic the chronic exposure scenario. Very few studies have also 
focused on the feasibility of reversing the vascular effects of ergot alkaloids using 
pharmacological antagonists. If such antagonists prove useful experimentally, they could 
be used therapeutically especially in early stages of exposure.  
 
Ergot exposure is also known to cause abortion in pregnant animals or reduced fetal 
weight in newborns. Since these alkaloids cause vasoconstriction in peripheral vascular 
bed, it is plausible to think that they have similar effects on the umbilical vein and 
arteries and may thus alter blood circulation in the fetus.  
 
Two separate experiments were conducted to address the above questions. In the first, to 
mimic acute exposure, animals were orally exposed to a single oral dose of ergot 
alkaloids. Since the pedal artery is commonly affected in animals suffering from 
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gangrene, this artery was selected to examine the roles of α1- adrenergic receptors and 
serotonergic receptors in mediating the acute vascular contractile effects. The effect of a 
selective α1-adrenergic receptor antagonist was also examined to evaluate its usefulness 
in reducing the vascular contractile effects of ergot alkaloids. 
 
In the second experiment, pregnant sheep were orally exposed to ergot alkaloids for 45 
days. The concentration of ergot alkaloids used in this study mimicked the low dose 
typically seen in a real exposure scenario. The umbilical artery and vein were dissected 
after euthanasia and the role of α1- adrenergic receptors in mediating the contractile 
effects of ergot alkaloids was examined. The pedal artery of the dam was also dissected 
and examined similarly.  
 
2.2 Hypotheses 
 
1. Acute single dose oral exposure to ergot alkaloids results in an increased contractile 
response in the pedal artery and is mediated through the activation of α1- adrenergic and 
serotonergic receptors.  
 
2. The acute vascular effects of oral exposure to ergot alkaloids can be reversed via the 
selective α1-adrenergic antagonist, TE.  
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3. Exposure to ergot alkaloids for 45 days results in an increased contractile response in 
the umbilical artery and vein as well as the maternal pedal artery; an effect that is 
mediated by the activation of α1- adrenergic receptors.  
 
2.3 Objectives 
 
1. To examine the acute vascular effects of single-dose oral exposure to ergot alkaloids 
on pedal arteries and the role of α1- adrenergic and serotonergic receptors in mediating 
these effects.   
 
2. To examine the feasibility of reversing the acute vascular contractile effects of single 
dose oral exposure to ergot alkaloids using a selective α1-adrenergic antagonist, TE.  
 
3. To examine the vascular contractile effects of 45-day exposure to ergot alkaloids on 
the umbilical and pedal vasculature and to examine the role of α1- adrenergic receptors in 
mediating these effects.   
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3.1 Abstract 
 
Ergotism is a common and increasing problem in Saskatchewan’s livestock. Chronic 
exposure to low concentrations of ergot alkaloids is known to cause severe arterial 
vasoconstriction and gangrene through the activation of adrenergic and serotonergic 
receptors on VSMC. The acute vascular effects of a single oral dose with high-level 
exposure to ergot alkaloids remain unknown and are examined in this study. This study 
had two main objectives; the first was to evaluate the role of α1-adrenergic and 
serotonergic receptors in mediating the acute vasocontractile response after single-dose 
exposure in sheep. The second was to examine whether terazosin could abolish the 
vascular contractile effects of ergot alkaloids.   
 
Twelve adult female sheep were randomly placed into control and exposure groups (n = 
6/group). Ergot sclerotia were collected and finely ground. The concentrations of six 
ergot alkaloids (ergocornine, ergocristine, ergocryptine, ergometrine, ergosine and 
ergotamine) were determined using HPLC/MS at Prairie Diagnostic Services Inc, 
(Saskatoon, SK, Canada). Each ewe within the treatment group received a single 
treatment of ground ergot sclerotia at a dose of 600 µg/kg BW (total ergot) while each 
ewe in the control group received water. Animals were euthanized 6 hours after the 
treatment, and the pedal artery (dorsal metatarsal III artery) from the left hindlimb from 
each animal was carefully dissected and mounted in an isolated tissue bath. The vascular 
contractile response to PE (α1-adrenergic agonist) was compared between the two groups 
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before and after TE (α1-adrenergic antagonist) treatment. The vascular contractile 
response to 5-hydroxytryptamine (5-HT also known as serotonin) was also assessed.  
 
Acute exposure to ergot alkaloids resulted in a 38% increase in PE contractile response 
compared to control (Ctl EC50=1.74 x 10
-6 M; Exp EC50 = 1.079 x 10
-6 M, P = 0.046).  
TE treatment resulted in a significant dose-dependent increase in EC50 in both exposure 
and control groups (P < 0.05 for all treatments). Surprisingly, TE effect was significantly 
more pronounced in the ergot exposed group compared to the control group at two of the 
three concentrations of TE (TE 30 nM, P = 0.36; TE 100 nM, P < 0.001; TE 300 nM, P < 
0.001). No significant difference was found in serotonin contractile response between the 
two groups (P > 0.05).  
                                                                                                                                                                                                                                                          
Similar to chronic exposure, acute exposure to ergot alkaloids results in increased 
vascular sensitivity to PE, but not serotonin. TE is a more potent dose-dependent 
antagonist for the PE contractile response in sheep exposed to ergot compared to the 
control group. This study may indicate that the dry gangrene seen in sheep, and likely 
other species, might be related to the activation of α1-adrenergic receptor. This effect may 
be reversed using TE especially at early stages of the disease before cell death occurs. 
This study may also indicate that acute single dose exposure scenario may be useful in 
the study of vascular effects of ergot alkaloids.  
 
Keywords: acute ergot exposure, ergot toxicity, sheep, vasoconstriction, adrenergic 
receptors 
33 
 
3.2 Introduction 
 
Ergot poisoning remains an economically important disease affecting a variety of animal 
species including cattle, sheep, horses, and goats with estimated annual losses of more 
than a billion dollars within the US 41. Ergot poisoning is caused by the prolonged 
consumption of ergot alkaloids which are naturally occurring mycotoxins produced by 
fungi infecting crops such as triticale, cereals, and grains such as barley, wheat and 
durum 11, 37, 105. The most widely encountered species of ergot alkaloid producing fungi in 
Western Canada and Europe are in the family of Clavicipitaceae 28, 64, 68. This fungal 
family includes the external spore-producing fungi (Claviceps spp.) and endophytic fungi 
(Neotyphodium spp.). The major species causing agricultural problems in Western 
Canada is Claviceps purpura 64, 68 . The active ingredients of ergot alkaloids are confined 
and concentrated within the sclerotia which are external fungal bodies 91. Clinical signs of 
lameness, hoof loss, and dry gangrene of the lower limbs, tail, ear tips and teats are 
commonly seen in chronic ergotism and are related to the effect of ergot alkaloids on the 
vasculature causing severe vasoconstriction 15, 101, 102.  
 
The precise in vivo vasoactive mechanisms of ergot alkaloids have not been determined. 
However, in vitro tissue bath studies, where normal dissected and isolated arterial rings 
were exposed to purified ergot alkaloids, have previously shown that the adrenergic and 
serotonergic receptors on vascular smooth muscles are activated. This is also supported 
by the fact that the chemical structure, i.e., ergoline ring, of ergot alkaloids resembles that 
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of physiologic neurotransmitters such as dopamine, norepinephrine, epinephrine, and 
serotonin which are known to be vasoactive 105.  
 
It is important to note that despite the rapid metabolism and excretion of ergot alkaloids 
which occurs within several hours after exposure 39, 106, the clinical vascular 
manifestations of ergot alkaloids are always seen after the prolonged (several weeks to 
months) consumption of ergot-contaminated plants. While these clinical vascular 
manifestations could be explained by the repeated exposure to ergot alkaloids, these 
effects often remain long after the ergot-contaminated feed is removed! Recent evidence 
suggests that ergot alkaloids may bioaccumulate within the vasculature 53, 83. It is also 
possible that other unknown vasoactive mechanisms may be involved in mediating these 
effects. 
 
It is unknown whether acute ergot exposure affects vascular contractility in a similar 
manner to chronic exposure.  If similar effects are found, then acute exposure scenarios 
may be useful to study the mechanisms of vascular alteration by ergot alkaloids. Many 
studies have focused on finding an antagonist to counteract the clinical effects of 
ergotism. For example, dopamine antagonists have been shown to partially reverse the 
effects of the low prolactin levels produced by ergot alkaloids. Similarly, ketanserin, a 5-
HT2 antagonist, has been reported to reduce the contractile effects of the uterine and 
umbilical arteries. Elucidating the mechanisms of vascular contractile response induced 
by ergot alkaloids may prove useful to identify treatment options for the vascular-related 
clinical manifestations of ergot poisoning.   
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This study aimed to examine the role of adrenergic and serotonergic receptors in 
mediating the vascular effects of ergot alkaloids after an in vivo acute exposure scenario 
to these alkaloids. PE (an α1-adrenergic agonist) contractile response was compared 
between ergot exposed and control groups before and after TE (α1 –adrenergic antagonist) 
treatment. The contractile response of 5-hydroxytryptamine (5-HT, also known as 
serotonin) was also assessed.  
 
We hypothesized that an acute single dose oral exposure to ergot alkaloids results in an 
increased contractile response in the pedal artery; an effect that is mediated through the 
activation of α1-adrenergic and serotonergic receptors. We also hypothesized that the 
acute vascular effects of oral exposure to ergot alkaloids can be reversed via TE (the α1- 
adrenergic antagonist).  
 
3.3 Materials and Methods 
 
3.3.1 Animals 
 
All protocols were approved by the Animal Care and Ethics Committee at the University 
of Saskatchewan. Before the experiment, all animals were weighed and clinically 
examined with body temperature and heart rate recorded. A blood sample was also 
collected from each animal, and a complete blood count was performed evaluating red 
and white blood cell counts as well as platelets count and total plasma protein to ensure 
that all animals were healthy. 
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3.3.2 Tissue Collection 
 
Twelve healthy adult ewes were randomly assigned into treatment or control groups (n = 
6 / group). Animals were allowed to acclimatize for fourteen days and were fed alfalfa 
hay and water ad libitum. Ergot alkaloids containing sclerotia were collected, finely 
ground and the concentrations of six alkaloids (ergocornine, ergocristine, ergocryptine, 
ergometrine, ergosine and ergotamine) were determined using HPLC/MS at Prairie 
Diagnostic Services Inc., (Saskatoon, SK, Canada) 56. Each ewe within the treatment 
group received a single dose of ground ergot sclerotia at a dose of 600 µg/kg BW (total 
ergot) dissolved in 50 mL of water via a stomach tube. The concentrations of ergot 
alkaloids within sclerotia are recorded in Table 3.4-1. The control group received water 
placebo. Six hours after treatment animals were euthanized using a captive bolt, and a 
necropsy was performed. A 15 cm segment of the pedal artery (dorsal metatarsal artery 
III) was carefully dissected and collected from each animal, soaked in a diluted heparin 
solution (10 Unit/1mL) and transferred into a container containing modified Krebs-
Henseleit buffer solution [in mM: 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 22.0 
NaHCO3, 5.0 glucose and 2.5CaCl2; Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada) 
(pH 7.4 gassed with 95%O2, 5%CO2 at 37˚C)] on ice until transport to the laboratory. 
Immediately upon arrival to the lab, adipose and connective tissue were carefully 
removed from each arterial segment and sliced into four 3 to 5 mm cross sections. Each 
arterial section was suspended between the bases of two triangular-shaped wires within 
an isolated 10 mL tissue bath (Chengdu equipment manufacturing, China) containing 
modified Krebs-Henseleit buffer solution maintained at the above conditions. Arterial 
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rings were allowed to equilibrate for 1 hour under a resting tension of 2 grams with the 
bath solution changed every 15 minutes. Arterial rings were treated with PE (1 x 10-6 M) 
(Sigma-Aldrich Canada Ltd. Oakville, ON, Canada) to initiate contraction and to confirm 
tissue viability and responsiveness. The tissues were later washed with incubation buffer 
until resting tension was achieved.  
 
3.3.3 Contractile Response 
 
Three vascular rings from the pedal artery of each animal were used to assess the PE 
contractile response before and after the incubation of each ring with a different 
concentration of TE. The vascular contractile response to 5-HT was also assessed in the 
fourth arterial ring. Initially, a cumulative concentration-dependent contraction in 
response to PE was obtained by adding increasing concentrations of PE (1 x 10-9 M to 1 x 
10-4 M). After each PE treatment, arterial rings were allowed to achieve maximum 
tension which plateaued for 2 minutes before the next concentration was added. After the 
last PE treatment, arterial rings were allowed to return to resting tension with buffer 
replacement occurring every 15 minutes for 1 hour. This was followed by incubating 
each of the three rings with 30, 100 or 300 nM TE for 20 minutes after which the 
cumulative PE contractile response was repeated in each chamber as above. A similar 
cumulative contractile response for 5-HT was obtained in the fourth ring by adding 
increasing concentrations of 5-HT (1 x 10-9 M to 1 x 10-4 M). Following completion of 
the exposure, all rings were exposed to 1 x 10-6 M PE to verify their viability.  
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3.3.4 Data Collection, Analysis and Statistical Analysis 
 
All measured isometric contractile responses were recorded in grams of tension using 
‘Chart’ software and Powerlab equipment (AD Instruments Inc., Colorado Springs, CO, 
USA). For each PE or 5-HT treatment, the maximum tension in grams achieved before 
the 2 minutes plateau period was recorded and corrected for a baseline. To minimize 
variation due to arterial size, each contractile response from an individual ring was 
normalized to its maximum contractile tension induced by 1 x 10-4 M PE or 5-HT 
treatment.   
 
Contractile response data were presented as percentage means ± SEM of the maximum 
contractile effect induced by 1 x 10-4 M PE or 5-HT treatment. For each treatment type, a 
sigmoidal dose-response curve was plotted using nonlinear regression with variable slope 
utilizing GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA) which was later used 
to calculate potency presented as the concentration producing 50% of the maximum 
response (EC50). Results were presented as the log of the EC50 value. Statistical 
differences in EC50 among the different dose-response curves were calculated by the 
extra sum-of-squares F-test were a P-value less than 0.05 was considered significant.  
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3.4 Results 
 
All animals remained healthy after treatment and did not exhibit any clinical signs during 
the 6 hours period between the administration of ergot alkaloids and euthanasia. No gross 
or histological changes were seen in either group in the lung, liver, kidneys, heart, spleen, 
intestines, fat and pedal arteries.   
 
3.4.1 Phenylephrine Dose Response Curve Compared Between Ergot Exposure 
and Control Groups 
 
In the control group, the PE contractile response was first observed at 1 x 10-7 M 
concentration, and the maximum contractile response recorded at the highest PE 
concentration (1 x 10-4 M) was 22.8 grams. The contractile response in the exposure 
group was first observed at 0.5 x 10-7 M while the highest PE concentration yielded a 
maximum contraction of 18.0 grams. Ergot exposure resulted in a significant decrease in 
EC50 compared to the control group (P = 0.0462). Comparisons of PE contractile 
responses between the two groups are presented in Figure 3.4-1. Details of EC50 are for 
all groups are presented in Table 3.4-2. 
 
3.4.2 Effect of Terazosin Treatment on Phenylephrine Dose Response Curve  
 
In the control group, TE treatment resulted in a significant and dose-dependent increase 
in EC50 (P < 0.0001 for all concentration; 30, 100 and 100 nM). Similarly, EC50 
significantly increased in a dose-dependent manner in the exposure group after terazosin 
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treatment (P < 0.0001 for all concentration; 30, 100 and 100 nM). See Figures 3.4-2 and 
3.4-3 for details. The blocking effect of TE was greater in the exposure group when 
compared to the control group when given at 100 nM and 300 nM (P < 0.0001). See 
Figures 3.4-5 and 3.4-6. A similar trend of increasing EC50 in the exposure group 
compared to the control group after the 30 nM TE treatment was seen, but the difference 
was not statistically significant (P = 0.076), Figure 3.4-4. (See Table 3.4-2 for details.)  
 
3.4.3 Serotonin Dose Response Curve Compared Between Exposure and Control  
 
No significant difference was found in EC50 compared between the control and exposure 
group.  
 
 
 
 
 
 
 
 
 
 
 
41 
 
3.4.4 Results Tables 
 
Table 3.4-1 The concentration of six ergot alkaloids determined within ground sclerotia 
using HPLC/MS*.  The total concentration of these alkaloids was used to formulate a 
single oral dose (600 µg/kg BW) which was administered to each sheep using a stomach 
tube.  
 
 
 
Alkaloid 
Concentration (ppb) 
Dry weight 
Oral dose (µg/kg BW) 
Ergocornine 216500 26.4 
Ergocristine 3653000 445.9 
Ergocryptine 540100 65.9 
Ergometrine 78850 9.6 
Ergosine 89570 10.9 
Ergotamine 338300 41.3 
Total 4915900 600 
*The detection limit for each alkaloid was 1.25 ppb. 
HPLC/MS, high performance liquid chromatography and mass spectrometry; µg/kg BW, 
microgram per kilogram body weight; ppb, part per billion 
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Table 3.4-2 PE EC50 compared between ergot exposed and control sheep (n = 6/group) 
before and after terazosin treatment in dissected pedal arteries using an arterial tissue 
bath.  Ergot exposed sheep received a single oral dose of 600 µg/kg BW total ergot 
dissolved in a water based on the levels of six ergot alkaloids determined previously. 
Control sheep received a water placebo treatment. The effect of terazosin was determined 
using three increasing concentrations of terazosin; 30,100 and 300 nM. The serotonin 
EC50 was also determined in dissected pedal arteries and compared between the two 
groups. For each treatment type, a sigmoidal dose-response curve was plotted using 
nonlinear regression which was used to calculate EC50. Statistical differences in EC50 
among the different treatment types were calculated by the extra sum-of-squares F-test. A 
P-value less than 0.05 was considered significant. 
 
 
 
Tissue bath 
Treatment Type 
 
 
Control 
EC50 and 95% CI 
 
 
Ergot Exposed 
EC50 and 95% CI 
 
P -value 
PE 1.74 x 10-6 (1.39 x 10-6 - 2.18 x 10-6) a, d 1.08 x 10-6 (7.4 x 10-7 -  1.57 x 10-6) a, g P <0.05 
PE + TE (30nM) 6.11 x 10-6 (4.78 x 10-6 - 7.8 x 10-6) d, e 7.74 x 10-6 (4.63 x 10 -6 - 1.3 x 10-5) g, h P = 0.37 
PE + TE (100nM) 9.6 x 10-6 (7.69 x 10-6 - 1.2 x 10-5) b, e, f 2.57 x 10-5 (1.7 x 10-5 – 3.9 x 10-5) b, h, i P <0.0001 
PE + TE (300nM) 1.77 x 10-5 (1.34 x 10-5 - 2.33 x 10-5) c, f 6.73 x 10-5 (4.24 x 10-5 – 1.07 x 10-4) c, i P <0.0001 
5-HT 5.01 x 10-7 (2.3 x 10-7 – 1.09 x 10-6) 1.65 x 10-6 (7.19 x 10-7 – 3.77 x 10-6) P = 0.12 
a, b, c, d, e, f, g, h, i letters with the same superscript are significantly different 
  
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; µg/kg BW, microgram per kilogram body weight; PE, phenylephrine; TE, 
Terazosin; CI, confidence interval; 5HT, 5-hydroxytryptamine (serotonin); nM, 
nanomolar 
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3.4.5 Result Figures 
 
Figure 3.4-1 Mean arterial contractile responses to increasing concentration of PE 
compared between control and ergot exposed group.  The pedal artery was collected 6 
hours after single oral exposure to 600 µg/kg BW (total ergot) or after placebo water 
treatment (n = 6 / group). Contractile response data were presented as percentage means 
± SEM of the maximum contractile effect induced by 1 x 10-4 M PE treatment. Ergot 
exposure resulted in a significant decrease in EC50 compared to the control group (P < 
0.05).  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; BW, body weight; CTL, control group; EXP, exposure 
group; M, Molar 
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Figure 3.4-2 Mean arterial contractile responses to increasing concentration of PE in 
control animals compared before and after 30, 100 or 300 nM TE treatment (n = 6).  
Contractile response data were presented as percentage means ± SEM of the maximum 
contractile effect induced by 1 x 10-4 M PE treatment. TE treatment resulted in a 
significant dose-dependent increase in EC50 compared to PE alone (P < 0.0001).   
 
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; TE, terazosin; M, Molar; nM, nanomolar 
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Figure 3.4-3 Mean arterial contractile responses to increasing concentration of PE in 
ergot exposed animals compared before and after 30, 100 or 300 nM TE treatment (n = 
6).  Contractile response data were presented as percentage means ± SEM of the 
maximum contractile effect induced by 1 x 10-4 M PE treatment. TE treatment resulted in 
a significant dose-dependent increase in EC50 compared to PE alone (P < 0.0001).   
 
 
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; TE, terazosin; Exp, exposure group; M, Molar; nM, 
nanomolar 
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Figure 3.4-4 Mean arterial contractile responses to increasing concentration of PE 
compared between control and ergot exposed groups after TE treatment at 30 nM. EC50 
was not significantly different between the two groups (P = 0.37). Contractile response 
data were presented as percentage means ± SEM of the maximum contractile effect 
induced by 1 x 10-4 M PE treatment.  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; TE, terazosin; CTL, control group; EXP, exposure group; 
M, Molar; nM, nanomolar 
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Figure 3.4-5 Mean arterial contractile responses to increasing concentration of PE 
compared between control and exposure after TE treatment at 100 nM.  EC50 was 
significantly different between the two groups (P < 0.0001). Contractile response data 
were presented as percentage means ± SEM of the maximum contractile effect induced 
by 1 x 10-4 M PE treatment.  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; TE, terazosin; CTL, control group; EXP, exposure group; 
M, Molar; nM, nanomolar 
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Figure 3.4-6 Mean arterial contractile responses to increasing concentration of PE 
compared between control and exposure after TE treatment at 300 nM.  EC50 was 
significantly different between the two groups (P < 0.0001). Contractile response data 
were presented as percentage means ± SEM of the maximum contractile effect induced 
by 1 x 10-4 M PE treatment.  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; TE, terazosin; CTL, control group; EXP, exposure group; 
M, Molar; nM, nanomolar 
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3.5 Discussion 
 
The biological effects of ergot alkaloids on livestock are known to be diverse. This 
diversity is not only related to differences in alkaloid concentration and specific alkaloid 
in different plants, but also due to their ability to affect multiple biological processes27, 28, 
105. The ergoline ring system, which is a structure common to ergot alkaloids, is similar to 
the ring structure of epinephrine, dopamine, and serotonin thus allowing ergot alkaloids 
to mimic their function. In the vasculature, ergot alkaloids bind with a variety of 
serotonergic and adrenergic receptors to modify vascular tone 15. The effects of these 
alkaloids are known to be diverse with differing potencies among different animal 
species, however, within a species, the effects are dependent on the animal’s general 
health, body condition, reproductive status and previous exposure 104, 105.  
 
Ergotism in livestock is known to cause dry gangrene due to severe vasoconstriction 
within peripheral vasculature. Ergotism occurs after the prolonged ingestion of ergot 
alkaloids. Therefore, previous studies have focused on examining the mechanisms of 
vasoconstriction following chronic exposure scenarios 23, 31, 47. Thus, the vascular effects 
following acute exposure remain unknown. In this study, we wanted to investigate the 
role of α1-adrenergic receptor activation on vascular contractile response following a 
single acute high-dose of oral exposure scenario to ergot alkaloids using sheep as a 
model. Similar to other livestock species, sheep are chronically affected by ergotism and 
develop dry gangrene after prolonged exposure. We chose to examine the pedal artery 
due to its peripheral location on the ovine limb.  
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Ideally, pure individual ergot alkaloids should be used in prolonged feeding trials to 
precisely examine their vascular effects and the mechanism of these effects. However, 
because pure ergot alkaloids are very expensive, previous studies often used ergot or 
endophyte-infected tall fescue. It is often difficult to accurately estimate the individual 
dose in these studies as the concentration of alkaloids within feed is subject to significant 
variability due to feed storage conditions and uneven distribution. Alternatively, pure 
individual alkaloids are often used on dissected arteries to examine their vascular 
contractile effects in vitro using arterial tissue bath systems. In order to achieve a more 
defined dosing protocol, we used ground sclerotia in which the concentration of six 
different ergot alkaloids was determined 27, 56. The dose was adjusted in every animal 
depending on the body weight to receive a dose of 600 µg/kg BW of total ergot alkaloid 
content.     
 
It is known that the degree of vasoconstriction induced by ergot alkaloids is alkaloid 
dependent. For example, the vasoconstrictive effect elicited by ergocryptine is 100 times 
less potent as compared to ergotamine whereas ergocristine and ergocornine are 10 times 
less potent. Ergovaline, the predominant alkaloid in tall fescue grass, is thought to have a 
similar potency to ergotamine 15, 94. The potency of these alkaloids varies depending on 
their relative binding affinity to α-adrenergic and serotonergic receptors and their ability 
to specifically activate them. Most studies examining the vascular effects of ergot 
alkaloids have focused on studying the serotonergic receptors 22, 47, 50, 72. However, very 
few studies examined the activation of α-adrenergic receptors by different alkaloids. For 
example, the contractile response in the lateral saphenous vein of cattle grazing tall 
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fescue was significantly enhanced compared to control animals by BHT-920, an α2-
adrenergic agonist, but not by PE (α1-adrenergic agonist) 74. In addition, Schӧning et al. 
reported that ergovaline stimulated α1-adrenergic receptors but with low efficacy in rat 
thoracic aorta 94. In vivo studies focusing on heart rate and blood pressure changes after 
exposure to ergot alkaloids also indicate α-adrenergic receptor activation. Bradycardia 
induced by ergotamine in anesthetized rats was reduced by yohimbine, an α2-adrenergic 
antagonist. In addition, ergotamine treatment reduced the tachycardia induced by 
electrical stimulation of the spinal cord, and the reduction was similarly blocked after 
yohimbine treatment 88. Similarly, in rats, ergotamine has been shown to act as an agonist 
on α2-adrenergic receptors and an antagonist on α1-adrenergic receptor 87.  In our study, a 
significant increase in PE contractile response was found in ergot exposed sheep 
compared to control animals which might suggest that α1-adrenergic receptors mediate 
that response.  
 
Similar to what we expected, TE decreased the PE contractile response in ergot exposed 
and control sheep due to its antagonistic effects on the α1-adrenergic receptor. However, 
surprisingly, the potency of TE as an α1-adrenergic receptor antagonist was significantly 
enhanced in ergot exposed sheep compared to controls. It has been recently shown that 
previous exposure to high concentrations of ergot alkaloids may decrease vascular 
contractility making the vasculature less susceptible to the effects of ergot alkaloids. 
Klotz et al. examined the contractile response to ergovaline in cattle chronically grazing 
high and low-endophyte-infected tall fescue 50. This study demonstrated that the 
maximum contractile response was significantly higher in steers consuming low-
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endophyte-infected tall fescue. This is contrary to other studies, which found that the 
increase in vascular contractile response to ergot alkaloids is dose-dependent 61, 72. It is, 
thus, possible that the vascular contractile effect of ergot alkaloids is dose-dependent but 
may become less effective at very high doses.  It is possible that the high dose of ergot 
alkaloids we used resulted in a relatively low contractile response, and also enhanced the 
blocking effect of TE resulting in a reduced contractile response compared to control 
tissues.  
 
Alternatively, it is also possible that the effect of the blocker was enhanced in the ergot 
exposed group due to the unique mixture of alkaloids in the diet. Interestingly, it has been 
shown that the presence of ergocristine, ergocornine and ergocryptine together produces 
adrenergic blockade 24, 100, 109. Additionally, Roquebert and Demichel reported that 
ergocristine acts as an α1-adrenergic blocker in rat tail artery 86, 87, 89. Ergocristine had the 
highest concentration in the diet used in this study and may have acted as an antagonist. 
The enhanced blocking effect of TE in ergot exposed animals may indicate that this 
blocker may be useful in counteracting the vascular effects of ergot alkaloid exposure.  
 
Several studies have shown that ergot alkaloids interact with serotonin receptors in 
chronic exposure scenario 22, 47, 72. Contrary to this, we found no significant difference in 
contractile response between the two groups suggesting that serotonin may not affect 
vascular contractility after acute exposure. In agreement with our finding, Kalkman et al. 
reported that in rats injected intravenously with ergometrine the vasoconstrictor response 
was related to the activation of α1- and α2-adrenergic receptors, but not serotonergic 
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receptors 43. High-level exposure in ruminants can result in nervous signs such as 
hyperexcitability, hypermetria and tremors 15, 17.   The dose we used was relatively high, 
but was well tolerated by all animals with none showing clinical signs of illness.  
 
Currently, ergot toxicity is thought to be only related to the prolonged consumption of 
ergot alkaloids, and it is presumed that a short-term exposure will have no significant 
clinical effects. However, we show for the first time that even a single oral dose of ergot 
alkaloids causes a significant contractile response in arteries supplying distal extremities. 
This finding is of significance to the livestock industry and regulators as it may indicate 
that in cold weather conditions, short-term exposure to ergot alkaloids may result in 
significant decrease in blood supply to the extremities making animals prone to gangrene. 
It would be interesting to examine whether a similar but lower level of exposure scenario 
would result in a similar contractile response in livestock. In addition, it is also important 
to examine the effects of a short-term exposure on other systems as it is now presumed 
that the effects are only seen after chronic exposure. If similar negative effects are seen in 
other systems, it may indicate the need to lower the allowable limits of ergot alkaloids 
within feed to reflect the true nature of the negative impact of this disease.  
 
The finding that a blocking effect of TE was more potent in ergot exposed animals may 
indicate that this drug could be used to treat animals who have been recently exposed to 
ergot alkaloids. If it is proved to be useful, this drug may significantly reduce the 
economic impact of ergotism to the livestock industry. It also would be interesting to 
examine whether TE has any impact on other systems affected by this disease.  
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In summary, this study found that acute high-level exposure to ergot alkaloids results in 
increased vascular sensitivity to PE, but not serotonin and increases the effect of TE. 
Additional studies are immensely needed to examine the role of adrenergic, serotonergic 
and other receptors both in in vivo and in vitro.  
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PREFACE TO CHAPTER 4 
 
In the previous chapter, we demonstrated that acute ergot alkaloid exposure resulted in 
significant increase vascular contractile response to PE in the pedal artery. Since ergot 
toxicity in livestock mostly occurs after chronic exposure, and it is reported to result in 
abortion in pregnant animals, it is worthwhile to examine PE vascular contractile 
response during long-term and repeated exposure.  
 
In the next experiment, we used pregnant sheep as our model for a 45-day exposure 
experiment. We evaluated the contractile response in different vascular beds: the pedal 
artery and the umbilical vasculature to assess our questions following a 45-day exposure 
to ergot alkaloids in pregnant sheep. 
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CHAPTER 4: Effect of 45-day Ergot Alkaloid Exposure on the Phenylephrine  
Contractile Response of Maternal Pedal Artery, Umbilical Artery and Umbilical 
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4.1 Abstract 
 
Ergot alkaloids have been known to cause devastating effects in livestock. Ergot 
alkaloids act on the biogenic amine receptors and result in vascular disturbance as well as 
decreased reproductive performance. The objective of this study was to evaluate the 
activation of α1-adrenergic receptors in mediating vascular contractile response in the 
pedal artery (dorsal metatarsal III artery), the umbilical artery and the umbilical vein in 
pregnant sheep after long-term exposure to ergot alkaloids. 
 
Twelve pregnant sheep were randomly placed into control and exposure groups (n = 
6/group) after confirmation of approximately two months of gestation. The animals were 
maintained in a controlled environment with the ability to access to hay and water ad 
libitum. Daily ergot-contaminated feed pellets were given orally for 45 days to the 
exposure group (46.6 µg/kg BW total ergot alkaloids), while the control group received 
ergot-free pellets. The total concentration of major six ergot alkaloids (ergocornine, 
ergocristine, ergocryptine, ergometrine, ergosine and ergotamine) were determined using 
HPLC/MS at Prairie Diagnostic Services Inc., Saskatoon, SK, Canada. All animals were 
euthanized after 45 days of exposure. The maternal pedal artery from the left hindlimb, as 
well as an umbilical artery and vein from each animal, were carefully dissected and 
mounted in an isolated tissue bath. The vascular contractile response to a cumulative 
increasing dose of PE (α1-adrenergic agonist) was compared between the two groups.  
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Chronic exposure to ergot alkaloids resulted in 70.6% and 91.3% increase in PE 
contractile response in the umbilical artery (Ctl EC50 = 3.962 x 10
-6 M; Exp EC50 = 
1.161 x 10-6 M, P < 0.0001) and the umbilical vein (Ctl EC50 = 7.889 x 10
-6 M; Exp EC50 
= 6.801 x 10-7 M, P < 0.0001), respectively, when compared to the control group. There 
was no significant difference in PE contractile response in the maternal pedal artery 
between the two groups (P = 0.3927). Fetal weight from the ergot exposed group was 
significantly lower than control group (Ctl 3.3 ± 0.17 kg; Exp 2.07 ± 0.13 kg, P = 
0.0002). The increase in contractile response in the umbilical vein may result in 
decreased blood supply to the fetus causing decreased fetal weight. This is the first study 
to provide insight into the pathogenesis of the negative impact of ergot alkaloids on the 
umbilical vasculature in pregnant animals. Such an impact was seen at levels 
significantly lower than what is currently allowed by Canadian standards. Hence, it’s 
possible that many ergot-induced livestock abortions are being overlooked by 
diagnosticians due to the assumption that the levels of ergot alkaloids in the feed are 
acceptable. It is, therefore, essential that these standards be revised to ensure the safety of 
the livestock industry.  
 
 
Keywords: ergot toxicity, pregnant sheep, vasoconstriction, adrenergic receptors. 
 
 
 
 
59 
 
4.2 Introduction  
 
Ergot poisoning in livestock is caused by prolonged consumption of ergot alkaloids 
within fungi-infected cereal crops and grains such as barley, wheat, and durum. In 
Western Canada, the majority of ergot alkaloids are produced by fungi in the genus 
Claviceps with the most commonly incriminated species being Claviceps purpura 64, 68. 
Early signs of ergot poisoning in livestock include decreased milk production and 
lameness with the later progressing to complete hoof loss due to dry gangrene affecting 
the lower extremities101, 102. At this advanced stage, dry gangrene of the ear tips and tail 
end is often seen as these body parts are supplied by end arterioles 67, 69.  
 
Although heterogeneous in their chemical structures, all ergot alkaloids share the 
“ergoline ring”, the chemical structure of which resembles the physiological 
neurotransmitters: serotonin, dopamine, epinephrine and norepinephrine 29, 30, 37. This 
resemblance allows ergot alkaloids to bind and activate the various receptors of these 
neurotransmitters resulting in an enhanced response with undesired clinical 
consequences. For example, ergopeptines, a group of ergot alkaloids, are known to be 
potent dopamine agonists activating its D2 receptor.  The repeated activation of this 
receptor is responsible for decreased milk production through the inhibition of prolactin 
secretion 76. Similarly, the prolonged and repetitive activation of adrenergic and 
serotonergic receptors is thought to result in severe vasoconstriction ultimately causing 
gangrene in the extremities 34, 60, 98.  
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The consumption of ergot alkaloids is also known to have deleterious effects on pregnant 
animals 10, 80.  Clinically, signs of elevated rectal temperature, depression, weight loss due 
to reduced feed intake and progressive weakness are often seen and ultimately result in 
abortion 80, 101.  Reduced conception rate, shorter gestation period and reduced fetal 
weight have also been reported in farm animals 35.  
 
Throughout pregnancy, the umbilical blood flow increases to meet the nutritional 
demands of the growing fetus. The umbilical vein supplies the fetus with nutrients from 
the dam while the umbilical arteries remove unwanted wastes. Thus, any impairment of 
blood flow through umbilical vasculature may have a negative impact on the fetus 19, 35, 38, 
65. The umbilical vasculature receives no sympathetic innervation 25. Therefore, the 
regulation of vascular tone within the umbilical vasculature is mediated through several 
vasoactive catecholamines produced by the mother and the fetus. It is known that during 
fetal distress or fetal hypoxemia, the concentrations of these catecholamine change and 
alter umbilical flow 75, 78. 
 
While several studies have shown vasoconstriction and reduced blood flow in umbilical 
veins after exposure to ergot alkaloids using ultrasound, few examined the mechanisms 
of these vasoconstrictive effects 13, 18, 22, 113. The purpose of this study was to examine the 
effects of ergot alkaloid exposure during pregnancy on the maternal pedal artery, as well 
as the umbilical artery and vein of pregnant sheep. Another objective was to examine the 
role of α1- adrenergic receptor in mediating these effects. We demonstrated that after a 
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45-day in vivo exposure to ergot alkaloids, the umbilical artery and vein, but not the pedal 
artery, display enhanced PE contractile response.  
 
4.3 Material and Methods 
 
4.3.1 Animals 
 
All protocols involving the use of live animals have been reviewed and approved by the 
Animal Care and Ethics Committee at the University of Saskatchewan which complies 
with the guidelines of the Canadian Council on Animal Care.  
 
Twelve healthy pregnant Katahdin dams each weighing approximately 60 kg were used 
to conduct this study and were randomly assigned into control and exposure groups (n = 
6/group) after they were confirmed to be 2 months pregnant using ultrasound. Animals 
were first clinically examined with heart rate and body temperature recorded. A complete 
blood count was also performed on a jugular blood sample, which evaluated red and 
white blood cell counts as well as the platelet count and total plasma protein to ensure 
that the dams were healthy. Animals were kept indoors at an ambient temperature of 20 
°C at the Animal Care Unit of the Western College of Veterinary Medicine and were 
housed together. They acclimatized for a 10-day period where they were daily provided 
with 100 grams of control pelleted diet in a bucket. At 7:00 am every morning, each 
animal in the treatment group was individually bucket-fed approximately 100 grams of a 
pelleted diet containing 28,000 ppb total ergot (46.6 µg/kg BW total ergot alkaloid 
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content) for 45 consecutive days while the control group received a normal control diet. 
Within the treatment diet, the concentrations of six ergot alkaloids; ergocornine, 
ergocristine, ergocryptine, ergometrine, ergosine, and ergotamine were determined at 
Prairies Diagnostic Services (Saskatoon, Saskatchewan, Canada) using HPLC/MS 56 with 
a detection limit of 1.25 ppb. See Table 4.4-1 for details. All animals were allowed access 
to water and alfalfa hay ad libitum for the duration of the experiment.   
 
4.3.2 Tissue Collection 
 
At the end of the exposure period, all dams were euthanized by captive bolt followed by 
exsanguination. Immediately after, full necropsies were performed, and a 10 cm-long 
segment of the umbilical cord was collected approximately 10 cm away from the fetal 
umbilicus from each animal.  Another 10-cm segment from the pedal artery (dorsal 
metatarsal artery III) was carefully dissected and collected. All vascular segments were 
immediately placed into a container containing modified Krebs-Henseleit buffer buffer 
[in mM: 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 22.0 NaHCO3, 5.0 glucose and 
2.5CaCl2; Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada) (pH 7.4 gassed with 
95%O2, 5%CO2 at 37˚C)] on ice. The Kreb’s solution was later modified by adding 3 x 
10-5 M desipramine and 1 x 10-6 M propranolol (Tocris Bioscience, Minneapolis, MN, 
USA) to deactivate catecholamine-neuronal uptake and β-adrenergic receptors, 
respectively 72. All vascular segments were transported to the laboratory and placed into 
to a Petri plate containing modified Krebs-Henseleit buffer. All excessive connective 
tissue and the surrounding fat were carefully trimmed, and all vascular segments were 
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sectioned into approximately 2 to 3 mm rings. Each vascular ring was carefully placed 
into an individual triangular wire for suspension into an arterial tissue bath (Chengdu 
equipment manufacturing, China) containing 10 mL modified Krebs-Henseleit buffer 
(gassed with 95%O2, 5%CO2 at 37˚C) 72. All arterial rings were maintained under a 
preload tension of 1 gram during equilibration with buffer replacement every 15 minutes. 
The viability of all vascular rings was examined by inducing contraction with 
phenylephrine at 5 x 10-4 M (Sigma-Aldrich Canada Ltd. Oakville, ON, Canada). Once 
steady state response was achieved, i.e., the tonic response to PE plateaued, tissues were 
washed every 15 minutes with normal modified Krebs’ buffer until the original resting 
tension was restored. 
 
4.3.3 Contractile Response 
 
A cumulative PE contractile response was performed in each vascular ring by adding 
increasing concentrations of PE (1 x 10-8 M to 5 x 10-4 M) as previously described 72. A 
PE treatment was added every 4 minutes allowing maximum response to be achieved for 
each particular concentration. Arterial rings were allowed to achieve maximum tension 
after each PE treatment followed by a 4-minute contractile plateau before the next 
treatment. After adding the last concentration, tissues were washed three times, and the 
resting tension was restored with buffer replacement every 15 minutes.  All vascular 
segments were finally assessed for viability by exposure to PE at 5x10-4 M.  
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4.3.4 Data Collection, Analysis and Statistical Analysis 
 
All measured isometric vascular contractions in response to PE were recorded as change 
in gram of tension on a Chart software (Chart V4.0.1) using a Powerlab data acquisition 
system (AD Instruments Inc., Colorado Springs, CO, USA). Tension responses were 
corrected for baseline and normalized as a percentage of the maximum contractile 
response induced by 5x10-4 M PE in order to adjust for differences in individual tissue 
size and architecture. Contractile response data were presented as percentage means ± 
SEM of the maximum contractile effect induced by 5 x 10-4 M. For each vessel type, a 
sigmoidal dose-response curve was plotted utilizing nonlinear regression with variable 
slope using Graph Pad Prism 6 (GraphPad Software Inc., La Jolla, CA). From each dose-
response curve, the concentration required to produce 50% of maximum vascular 
contraction (EC50) was determined.  Statistical differences in EC 50 among the different 
dose-response curves were calculated by the extra sum of square F-test where a P-value 
less than 0.05 was considered significant. 
 
4.4 Results 
 
The daily dose of total ergot alkaloids at 46.6 µg/kg BW was tolerated by all animals 
which remained healthy and showed no signs of anorexia, diarrhea, hyperventilation or 
lameness as previously reported in pregnant sheep exposed to ergot35. No gross or 
histological lesions were found in the lung, liver, kidneys, heart, spleen, intestines, fat, 
placenta, pedal or umbilical arteries in either of the treatment or control animals. 
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4.4.1 Maternal Pedal Artery Phenylephrine Dose Response Curve Compared 
between Ergot Exposure and Control Groups  
 
No significant difference in EC50 was found between the control and the exposure groups 
in response to PE as shown in Figure 4.4-1. The PE contractile response was first 
observed at 1 x 10-7 M concentration in both groups and the maximum contractile 
response recorded at the highest PE concentration (5 x 10-4 M) was 14.81 grams in the 
control group, whereas the maximum contractile response recorded at the highest PE 
concentration in the exposure group was slightly higher at 18.2 grams. No significant 
difference was found in EC50 compared between the control and exposure group.  
 
4.4.2 Umbilical Artery and Vein Phenylephrine Dose Response Curve Compared 
between Ergot Exposure and Control Groups 
 
The mean contractile response of the umbilical artery to PE was first observed at 1 x 10-7 
M in the control group and at 0.5 x 10-7 M in the exposure group. The maximum 
contractile response in the control group recorded at the highest PE concentration (5 x 10-
4 M) was 1.30 grams, while the highest PE concentration in the exposure group yielded a 
maximum contraction of 4.5 grams. Ergot exposure resulted in a significant decrease in 
EC50 compared to control (P ≤ 0.001) as shown in Figure 4.4-2.  
 
The mean contractile response of the umbilical vein to PE in the control group was first 
observed at 1 x 10-7 M, whereas in the exposure group was observed at 0.5 x 10-7 M. The 
maximum contractile response recorded at the highest PE concentration (5 x 10-4 M) in 
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the exposure group was higher when compared to the control group which was recorded 
at 4.2 grams and 2.78 grams, respectively. Ergot exposure resulted in a significant 
decrease in EC50 compared to control (P ≤ 0.001). Comparisons of PE contractile 
responses of the umbilical artery between the two groups are presented in Figure 4.4-3. 
Details of EC50 are for all groups are present in Table 4.4-2. 
 
4.4.3 Phenylephrine Dose Response Curve Compared between Umbilical Artery 
and Vein in Ergot Exposure and Control Groups 
 
Compared to the umbilical artery, the umbilical vein of sheep not exposed to ergot 
alkaloids displayed significantly higher PE EC50 (UA Ctl EC50 = 3.96 x 10
-6 M; UV Ctl 
EC50 = 7.9 x 10
-6 M, P = 0.05). See Figure 4.4-5. After ergot exposure the PE EC50 of 
umbilical vein was significantly lower than that of the artery. (UA Exp EC50 = 1.16 x 10
-6 
M; UV Exp EC50 = 6.8 x 10
-7 M, P = 0.002). See Figure 4.4-6. 
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4.4.4 Result Tables 
 
Table 4.4-1 The concentration of six ergot alkaloids determined in the ergot-
contaminated feed pellets using HPLC/MS*. The total concentration of these alkaloids in 
feed pellet was used to formulate an oral dose (46.6 µg/kg BW) which was orally 
administered to each pregnant ewe once a day for 45 days.  
 
 
Ergot Alkaloid Concentration (ppb) 
Dry weight 
Oral dose (µg/kg BW) 
Ergocornine 3320 5.5 
Ergocristine 12440 20.6 
Ergocryptine 4730 7.8 
Ergometrine 2110 3.5 
Ergosine 1570 2.6 
Ergotamine 4000 6.6 
Total 28,200 46.6 
*The detection limit for each alkaloid was 1.25 ppb. 
HPLC/MS, high performance liquid chromatography and mass spectrometry; µg/kg BW, 
microgram per kilogram body weight; ppb, part per billion 
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Table 4.4-2 PE EC50 compared between ergot exposed and control sheep (n = 6/group) in 
dissected maternal pedal arteries, umbilical arteries and umbilical veins using an arterial 
tissue bath. Feed pellets were fed to both groups for 45 days with access to alfalfa hay 
and water ad libitum. Ergot exposed sheep received an oral dose of 46.6 µg/kg BW total 
ergot in ergot-contaminated feed pellets based on the levels of six ergot alkaloids 
determined previously. Control sheep received normal feed pellet. 
For each treatment type, a sigmoidal dose-response curve was plotted using nonlinear 
regression which was used to calculate EC50. Statistical differences in EC50 among the 
different treatment types were calculated by the extra sum-of-squares F-test were a P-
value less than 0.05 was considered significant.  
 
 
Blood vessels 
Control 
EC50 and 95% CI 
Ergot Exposed 
EC50 and 95% CI 
P-value 
Pedal artery 4.33 x 10-6 (3.34 x 10-6 – 5.58 x 10-6) 4.85 x 10-6 (3.75 x 10-7 –  6.27 x 10-6) P = 0.39 
Umbilical artery 3.96 x 10-6 (2.88 x 10-6 - 5.4 x 10-6) a 1.16 x 10-6 (9.69 x 10 -6 - 1.45 x 10-5) a P<0.0001 
Umbilical vein 7.9 x 10-6 (3.9 x 10-6 - 1.39 x 10-5) b 6.8 x 10-7 (4.78 x 10-7– 9.3 x 10-7) b P<0.0001 
a, b Letters with the same superscripts are significantly different 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; µg/kg BW, microgram per kilogram body weight; PE, phenylephrine; CI, 
confidence interval; nM, nanomolar 
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4.4.5 Result Figures 
 
Figure 4.4-1 Mean contractile responses to increasing concentration of PE of the 
maternal pedal artery between control and ergot exposed group. The pedal artery was 
collected after a 45-day in vivo exposure to ergot-contaminated feed pellet (total ergot 
alkaloids 46.6 µg/kg BW) or normal feed pellet (n = 6 / group). There is no significant 
difference in comparison of the EC50 between the both group (P = 0.39). Contractile 
response data were presented as percentage means ± SEM of the maximum contractile 
effect induced by 5 x 10-4 M PE treatment.  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; µg/kg BW, microgram per kilogram body weight BW; 
CTL, control group; EXP, exposure group; M, Molar 
 
 
 
 
 
70 
 
Figure 4.4-2 Mean contractile responses to increasing concentration of PE of the 
umbilical artery between control and ergot exposed group. The umbilical artery was 
collected after a 45-day in vivo exposure to ergot-contaminated feed pellet (total ergot 
alkaloids 46.6 µg/kg BW) or normal feed pellet (n = 6 / group). Ergot exposure resulted 
in a significant decrease in EC50 compared to the control group (P < 0.0001). Contractile 
response data were presented as percentage means ± SEM of the maximum contractile 
effect induced by 5 x 10-4 M PE treatment.  
 
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; µg/kg BW, microgram per kilogram body weight; CTL, 
control group; EXP, exposure group; M, Molar 
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Figure 4.4-3 Mean contractile responses to increasing concentration of PE of the 
umbilical vein between control and ergot exposed group. Umbilical vein was collected 
after a 45-day in vivo exposure to ergot-contaminated feed pellet (total ergot alkaloids 
46.6 µg/kg BW) or normal feed pellet (n = 6 / group). Ergot exposure resulted in a 
significant decrease in EC50 compared to the control group (P < 0.0001). Contractile 
response data were presented as percentage means ± SEM of the maximum contractile 
effect induced by 5 x 10-4 M PE treatment.  
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; µg/kg BW, microgram per kilogram body weight; CTL, 
control group; EXP, exposure group; M, Molar 
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Figure 4.4-4 Mean fetal weight (±SEM) from ewes fed ergot-contaminated feed pellets 
(total ergot alkaloids dose at 46.6 µg/kg BW) or normal feed pellet (n = 6/group) for 45- 
days during gestation. The mean fetal weight from the ergot exposed group was 
significantly lower than the control group (control, 3.3 ± 0.17 kg; exposure 2.07 ± 0.13 
kg, P = 0.0002), (T-test, GraphPad Prism). 
 
 
 
µg/kg BW, microgram per kilogram body weight; kg, kilogram 
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Figure 4.4-5 Comparison of mean contractile responses to increasing concentration of PE 
between umbilical artery and umbilical vein in control group. The umbilical artery and 
vein were collected after a 45-day in vivo study. Control group was fed a normal pelleted 
diet (n = 6). Umbilical artery PE EC50 was significantly lower than to that of umbilical 
vein (P = 0.05). Contractile response data were presented as percentage of means ± SEM 
of the maximum contractile effect induced by 5 x 10-4 M PE treatment. 
 
 
 
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; µg/kg BW, microgram per kilogram body weight BW; 
CTL, control group; EXP, exposure group; M, Molar; UA, umbilical artery; UV, 
umbilical vein 
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Figure 4.4-6 Comparison of mean contractile responses to increasing concentration of PE 
between umbilical artery and umbilical vein in exposure group.  The umbilical artery and 
vein were collected after a 45-day in vivo study. Exposure group was given ergot-
contaminated feed pellet (total ergot alkaloids 46.6 µg/kg BW) (n = 6). Umbilical vein 
PE EC50 was significantly lower than to that of umbilical artery (P = 0.002). Contractile 
response data were presented as percentage means ± SEM of the maximum contractile 
effect induced by 5 x 10-4 M PE treatment. 
 
 
 
EC50, the concentration of phenylephrine producing 50% of the maximum contractile 
response; PE, phenylephrine; µg/kg BW, microgram per kilogram body weight BW; 
CTL, control group; EXP, exposure group; M, Molar; UA, umbilical artery; UV, 
umbilical vein 
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4.5 Discussion 
 
The PE contractile response in the umbilical vasculature following chronic exposure to 
ergot alkaloids using a sheep model was evaluated. A similar effect was also examined in 
the maternal pedal artery. PE is a selective α1-adrenergic receptor agonist and, therefore, 
typically causes vasoconstriction in peripheral arteries 34, 85. Human umbilical arteries are 
known to respond to adrenergic and serotonergic receptor stimulation resulting in 
vasoconstriction and altered blood flow 9. Few studies have examined the response of 
sheep umbilical arteries to catecholamines. One study reported that serotonin and 
angiotensin were potent vasoconstrictors, while acetylcholine, epinephrine, and 
norepinephrine were less potent 21. In addition, the epinephrine and norepinephrine 
contractile responses were blocked by adrenergic blockers 22.  Ergot alkaloids are known 
to cause poor reproductive performance in livestock resulting in fetal death, 
mummification and abortion 35. Decreased fetal and organ weight have also been reported 
18. In mice, ergot alkaloids have been shown to cause failure of implantation and return to 
estrous as well as pregnancy interruption when administered in the diet 62.  
 
Since ergot alkaloids are known to cause vasoconstriction in peripheral arteries, it is 
plausible to think that they would have similar effects on the umbilical vasculature during 
pregnancy. However, to the authors’ knowledge, only a single report examined these 
effects in umbilical arteries.  Dyer examined the contractile response to ergovaline in 
isolated bovine uterine and umbilical arteries and reported that the contraction developed 
slowly over 2 hours and did not relax over a 3 hours period despite a repeated buffer 
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change indicating strong affinity to the vascular receptor. Interestingly, this contraction 
was antagonized by ketanserin tartrate, a non-selective antagonist of 5-HT2 receptors, but 
not prazosin or phentolamine, α-adrenergic antagonists. This study concluded that 5-HT2 
and not adrenergic receptors, were responsible for vasoconstriction 22, 113. Contrary to the 
previous report, our study found that both the umbilical artery and vein displayed 
enhanced PE contractile response, i.e., more vasoconstriction at α1-adrenergic receptor, 
compared to control blood vessels after chronic exposure.  Our study suggests that α1-
adrenergic receptors play an important role in mediating the effects of ergot alkaloids. 
Receptors activation may, in part, explain the reproductive problems seen in livestock 
after chronic exposure.   
 
It is important to note that the previous report studied the vascular effects of a single pure 
alkaloid, i.e., ergovaline, added to isolated arterial rings and not after actual oral 
exposure. In essence, it is known that compounds are modified by various physiologic 
processes after oral administration and a small change in the chemical structure of a 
compound can lead to altered potency or spectrum of activity 54. Therefore, the previous 
report does not take into account the real in vivo vascular effects of ergot alkaloids after 
their metabolism or the combined effects of multiple ergot alkaloids, typically present in 
a regular diet. Very little is known about the metabolism of ergot alkaloids and whether 
the metabolites are vasoactive. However, there is evidence that ergot alkaloids 
bioaccumulate in tissues and the prolonged duration of their action could be related to the 
presence of active metabolites and tight tissue binding 48, 53, 83. Others have also shown 
that alkaloid metabolism may result in decreased potency. For example, compared to 
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ergotamine, dihydroergotamine has been found to be less potent as a vasoconstrictor with 
α-adrenergic antagonistic activity 97. Thus, it appears that the change in potency is likely 
dependant on the specific alkaloid and metabolite involved. Moreover, the most abundant 
ergot alkaloids in Western Canada do not include ergovaline, which is a dominant ergot 
alkaloid found in endophyte-infected tall fescue.  
 
It is interesting to note that both the umbilical artery and vein were affected after 45-days 
of exposure. In human medicine, fetal status is commonly assessed by performing 
doppler ultrasound on umbilical arteries. An abnormal umbilical flow is considered a 
marker for uteroplacental insufficiency and is associated with fetal hypoxia and acidosis 
8. Similarly, reduced blood flow in the umbilical vein results in decreased delivery of 
nutrients to the fetus resulting in fetal death 18, 19, 75. Our report, in agreement with others 
18, 35, found decreased fetal weight after 45-days of ergot exposure which could be 
explained by the reduced blood flow in the umbilical arteries and veins.  Surprisingly, the 
PE contractile response in the maternal pedal artery was not different from control 
arteries after 45-days of exposure to ergot alkaloids. Other studies in non-pregnant 
animals have shown increased PE contractile response in the lateral saphenous vein of 
sheep 74.  
 
Pregnancy is known to be associated with remarkable, yet reversible, changes in maternal 
circulation resulting in altered maternal blood volume, cardiac output and peripheral 
vascular resistance 65. In human beings, it is estimated that cardiac output increases by 
40%, a change that is typically associated with a marked endothelium-dependent 
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peripheral vasodilatation.  This vasodilatation typically leads to 35% decrease in 
peripheral vascular resistance 25, 99 .  
 
In sheep, cardiac output, heart rate, and blood volume were shown to be significantly 
higher while systolic and diastolic pressure was shown to decrease during pregnancy 
compared to the post-partum period 65.  These changes in cardiovascular function 
parameters are associated with alterations in the contractile response within arterial 
vascular beds. For example, it has been shown that pregnancy results in 75% increase in 
mesenteric blood flow. To accommodate for this change, Kim et al., reported an 
increased acetylcholine stimulated relaxation of mesenteric arteries of pregnant guinea 
pigs compared to non-pregnant animals 46.  
 
The finding of no significant difference in pedal artery contractile response after ergot 
exposure could be related to the decreased peripheral vascular resistance associated with 
pregnancy. Alternatively, it is possible that during pregnancy, the α1-adrenergic receptor 
may not be an important mediator of the contractile response in this artery after 45-days 
of ergot exposure. The lack of a contractile response could also be related to the relatively 
low dosage selected in this study. It would be interesting to examine the serotonergic 
contractile response in this vascular bed during pregnancy to see if it is also affected.  
 
No abortion occurred, and no gross or histological lesions were found in the lung, liver, 
kidneys, heart, spleen, intestines, fat or pedal arteries were detected after 45-days of oral 
ergot exposure in our study. Contrary to our finding, Greatorex reported that pregnant 
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sheep receiving ergot alkaloids aborted and displayed tongue necrosis, intestinal 
inflammation and hemorrhage 35. The difference between the two studies is likely related 
to dose and regimen used as the previous study used a dose (1000 µg of ergotamine/kg 
BW) 20 times higher than the one used in our study (46.6 µg/kg).  This high oral dose 
was also repeated three to four times daily.  It is also possible that the vasculature of the 
tongue and intestine are more sensitive to ergot alkaloids during pregnancy in sheep. 
 
As expected, the umbilical artery, having thicker tunica media, displayed lower PE EC50 
compared to the unbiblical vein in control animals. Surprisingly, the effect of ergot 
exposure was more pronounced on the umbilical vein which displayed lower PE EC 50 
than the umbilical artery. This may indicate that the umbilical vein is more sensitive to 
the effects of ergot than the umbilical artery. 
 
It is important to note that the dosage used in this study is below the Canadian guideline 
limit for ergot alkaloids in sheep diet which is 3000 ppb 27, 28. The experiment was also 
performed indoors with an ambient temperature of 20°C. The current Canadian limit may 
overlook the negative effects associated with the consumption of ergot alkaloids in 
freezing climatic condition when peripheral blood flow is already restricted 14. Therefore, 
the absence of clinical manifestations in this study does not indicate that the used level of 
exposure is safe for this species in Western Canada.  
 
In conclusion, we report that umbilical artery and vein, but not the pedal artery of 
pregnant sheep display increased contractile responses after 45-days of oral ergot 
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exposure which is mediated by the activation of α1-adrenergic receptor. Future studies 
may focus on the role of serotonergic receptors in mediating these effects.   
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CHAPTER 5: Discussion and Conclusions 
 
Ergot alkaloids are known to be vasoactive causing severe vasoconstriction in livestock 
after the chronic ingestion of infected grains. The effect is thought to be mediated 
through the activation of adrenergic and serotonergic receptors. This thesis aimed to 
address two important questions which were not previously examined in the literature. 
The first was whether these ergot alkaloids are vasoactive after a single high dose acute 
oral exposure. Typically, studies examining the effects of ergot alkaloids in vivo require 
the prolonged consumption of ergot alkaloids in feed for several months in order to 
mimic the real exposure scenario. Such studies are costly and time-consuming; therefore, 
most studies rely on examining the effects of ergot alkaloids by directly applying them to 
dissected vascular beds. While this approach offers valuable information, it does not 
mimic the real exposure scenario of oral consumption. If acute exposure causes similar 
vasoactive effects as chronic exposure, then an acute exposure protocol may prove to be 
useful to evaluate the chronic effects without the need for prolonged exposure.  
 
We expected that the acute exposure would mimic the vasoactive effects of chronic 
exposure and would be mediated by the activation of adrenergic and serotonergic 
receptors. To our surprise, while a similar vasoconstrictive response was seen after acute 
exposure, only the adrenergic receptors were involved in mediating this effect! This may 
indicate that the acute exposure scenario may be useful in studying the adrenergic, but 
not the serotonergic effects of ergot alkaloids. One, however, has to be cautious not to 
completely dismiss the idea of serotonergic activation after acute exposure as the sample 
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size in this study was relatively small. Another interesting and yet unexpected finding of 
the acute study was that ergot exposed animals were more responsive to the effects of the 
α1-adrenergic blocker (TE) compared to control animals, which may indicate this blocker 
may be useful in reducing the vasoconstrictive effects in ergot exposed animals. It may 
also indicate that ergot alkaloids may shift in their effect from being agonists, or even 
partial agonists, to becoming complete antagonists in the presence of TE! In support of 
this, it has been shown that ergotamine may act as a partial α2-agonist and antagonist in 
dog femoral and saphenous veins, respectively 12. The response to TE with vasodilation 
in affected species may also have diagnostic clinical implications. It would also be 
interesting to examine how TE affects other biological processes affected by ergot 
alkaloids such lactation and pregnancy.  
 
One limitation of this study was our inability to accurately quantify the exact dose of 
exposure within ground sclerotia. Our analytical methods allow for the quantification of 
only six ergot alkaloids which are claimed to be the most abundant within sclerotia. 
While being abundant could be an indication of clinical significance, it is known that the 
vasoconstrictive potency of these alkaloids varies significantly with some being 100 
times more potent than others. For example, ergovaline, which is a dominant alkaloid in 
infected tall fescue, has a similar potency to ergotamine which is commonly detected in 
ergot sclerotia. However, other ergot alkaloids such as ergocristine and ergocornine are 
ten times less potent than ergotamine. Ergocryptine is reported to be the least potent from 
all major six ergot alkaloids examined in sclerotia.  In addition, the interaction of each 
ergot alkaloid to receptors is variable. For example, ergocristine can act on both α2-
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adrenergic receptors and α1-adrenergic receptors. Also, ergotamine has an effect on both 
adrenergic and serotonergic receptors. Therefore, our calculated total dose of ergot 
alkaloids may not accurately reflect the vasoactive potency of the present mixture, which 
is reported to have more than 40 different ergot alkaloids in sclerotia27, 28. Nonetheless, 
our approach seems to be more clinically and scientifically relevant as it mimics the real 
exposure scenario and takes into account the pharmacokinetic effects of ergot alkaloids. 
Our approach also considers other interactions which may affect receptor binding such as 
the presence of other inhibitors or stimulators administered medicinally.  
 
Another important aspect that this in vivo protocol provides is the effects of alkaloids 
considering the alkaloid metabolism taking place in the live animal.  Some alkaloids may 
become more potent while others may be less potent after metabolism. For example, 
compared to ergotamine, dihydroergotamine has been found to be a less potent 
vasoconstrictor with α-adrenergic antagonistic activity 97. 
 
Very little is known about the metabolism of ergot alkaloids and whether the metabolites 
are vasoactive. However, there is evidence that ergot alkaloids bioaccumulate in tissues 
and the prolonged duration of their action could be related to the presence of active 
metabolites and tight tissue binding 48, 53, 83. Others have also shown that alkaloid 
metabolism may result in decreased potency 97. Another limitation of this study was the 
sample size which was relatively small, still, significant detectable differences were 
found between groups.    
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The second important question in this thesis was whether vasoconstrictive effects are 
seen in the umbilical vasculature of pregnant animals after 45-days of oral ergot 
exposure. To our knowledge, no previous studies have addressed this important question 
despite the fact that ergot exposure is known to reduce fetal weight and to cause abortion. 
This study was limited to the effects on α1-adrenergic receptors within the umbilical 
vasculature.  
 
After a 45-day oral exposure in pregnant sheep, ergot alkaloids caused a significant 
increase in PE contractile response in both the umbilical artery and vein, but not in the 
maternal pedal artery. The increased contractility within the umbilical vein, associated 
with the finding of a decreased fetal weight, may indicate that ergot exposure may reduce 
blood supply resulting in decreased nutrients reaching the fetus and decreased fetal 
growth. The increased contractility within the umbilical artery may also have detrimental 
effects on fetal health as it may result in decreased waste removal from the fetus. The 
finding of no change in the maternal pedal artery contractility despite relatively long-term 
exposure to ergot alkaloids is likely related to the decrease in peripheral vascular 
resistance often associated with physiological changes during pregnancy. This is in 
contrast to what is seen in non-pregnant animals where pedal artery vasoconstriction after 
prolonged ergot exposure often leads to gangrene. It is also possible that the lack of effect 
reflects differences in receptor expression within the vasculature, changes between ergot 
and receptor interaction or altered metabolism and excretion during pregnancy. A less 
likely possibility is that the absence of effect is related to small sample size.  
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Although the current study contains a small sample size, the findings suggest that 
repeated exposure to ergot alkaloids, even at low concentrations, can be detrimental to 
livestock productivity. Fetal nutrient restriction is an important cause of increased 
neonatal morbidity and mortality in livestock 19. Decreased fetal or neonatal weight also 
results in decreased average daily weight gain resulting in significant losses to producers 
20. Low birth weight has further been associated with increased pre-weaning mortality 
and increased incidence of infections. As such, addressing the issue of high ergot levels 
in feed would likely have a significant economic impact for livestock producers, 
increasing livestock productivity, decreasing treatment cost and increasing profitability19, 
20.  
 
It is important to note that sheep are known to be less susceptible to ergotism than cattle 
and horses 27. It is thus likely that the vascular effects described in both studies performed 
here will be amplified and probably more clinically noticeable in these other two species 
45, 72. This indicates that gangrene and abortion in these other species may occur at even 
lower concentrations than the ones used in this study emphasizing the need to create 
species-specific standards to address the differences in species susceptibility. The fact 
that the effects seen in the second study occurred at concentration levels lower than what 
is permitted in livestock feed indicates the need to revise these standards to reflect the 
safety concerns associated with low-level exposure. 
 
Notwithstanding these limitations, the study suggests that allowable limits of ergot 
alkaloids in livestock feed need to be revised with consideration of the climate, species 
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and physiological stage of animals. The findings of these studies also shed light on the 
clinical implication of using adrenergic blockers as a treatment for ergot toxicity. Future 
studies should focus on examining the role of serotonergic receptors and other adrenergic 
receptors in mediating the effects of ergot alkaloids on the umbilical vasculature. It would 
also be interesting to examine the length of time the vasoconstrictive effect last within all 
examined vascular beds. 
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